NIH_SPENDING_CATS: Bioengineering;Clinical Research;HIV/AIDS;Infectious Diseases;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD)

ORG_CITY: FAIRFAX

ORG_NAME: GEORGE MASON UNIVERSITY

PHR: This proposed study integrates molecular simulations, artificial intelligence, functional anti-HIV assays, and animal models to explore the anti-HIV properties of a host protein PSGL-1. The study will provide new knowledge fundamental to understand PSGL-1's anti-HIV activity, and could offer new therapeutics for a functional cure of HIV infection.

PI_NAMEs: JAFRI, MOHSIN SALEET;KLIMOV, DMITRI KONSTANTINOVICH;WU, YUNTAO  (contact)

PROGRAM_OFFICER_NAME: ZHOU, YAN

PROJECT_TERMS: Affect;Algorithms;Amino Acid Sequence;Amino Acids;Animal Model;Artificial Intelligence;Binding;Binding Sites;Biological Assay;CD4 Positive T Lymphocytes;cell motility;Cell surface;Cells;Complex;Computing Methodologies;Coupled;Data;Data Set;design;Development;dimer;DNA;E-Selectin;engineered T cells;Engineering;experience;Extracellular Domain;Functional disorder;Glycoproteins;glycosylation;HIV;HIV Infections;Human Engineering;humanized mouse;in silico;in vivo;Individual;Infection;Knowledge;Laboratories;laboratory experiment;Leukocyte Rolling;Ligands;Lymphoid Cell;Machine Learning;Maps;Mediating;Membrane Glycoproteins;Membrane Proteins;migration;Modeling;Molecular;Molecular Conformation;molecular dynamics;molecular modeling;mouse model;Mucins;Mus;Mutagenesis;mutant;Mutate;Myeloid Cells;N-terminal;Natural Immunity;novel;novel strategies;novel therapeutics;overexpression;P-Selectin;P-selectin ligand protein;particle;Play;Polysaccharides;Positioning Attribute;predictive modeling;Process;Proline;Properdin;Property;Proteins;Research;Resistance;Role;Safety;Sampling;Selectins;Self-control as a personality trait;simulation;Site;solute;Stretching;Structure;Structure-Activity Relationship;Surface;T-Lymphocyte;Testing;Threonine;Validation;Variant;Vertebral column;Viral;Viral Physiology;Viral reservoir;Viremia;Virion;Virus;virus host interaction;Work

PROJECT_TITLE: Molecular Modeling of the DR domain of an HIV restriction factor PSGL-1

STUDY_SECTION: HVCD

STUDY_SECTION_NAME: HIV Molecular Virology, Cell Biology, and Drug Development Study Section[HVCD]


ADMINISTERING_IC: AI

ARRA_FUNDED: N

ED_INST_TYPE: SCHOOLS OF MEDICINE

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NIH_SPENDING_CATS: Genetics;HIV/AIDS;Infectious Diseases

ORG_CITY: CHARLOTTESVILLE

ORG_COUNTRY: UNITED STATES

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_FIPS: US

ORG_NAME: UNIVERSITY OF VIRGINIA

ORG_STATE: VA

PHR: Project Narrative Differences in the HIV Rev-Rev Response Element (RRE) regulatory axis allow the virus to adapt to different fitness environments. This project will elucidate how variations in the Rev-RRE system permit the virus to navigate the sexual transmission bottleneck and establish and maintain latency. Improved understanding of these mechanisms has the potential to inform the development of improved prophylaxis to prevent new infections and improved methods of perturbing latency to accomplish a cure.

PI_NAMEs: JACKSON, PATRICK EVAN HAGER (contact)

PROGRAM_OFFICER_NAME: NOVAK, LEIA KAYE

PROJECT_TERMS: Address;Affect;Anatomy;antiretroviral therapy;Autopsy;Binding;Binding Sites;Biological Assay;CD4 Positive T Lymphocytes;Cells;Circulation;Clinical;clinically relevant;Complex;Cytoplasm;Data;Data Set;Development;Environment;Equilibrium;experimental study;Female;fitness;Fluorescence;Future;Gene Expression;Genes;Genome;Goals;HIV;HIV Genome;HIV Infections;Immune;immune clearance;Immune Evasion;improved;Individual;Infection;Infection prevention;Interruption;Intervention;Introns;Kinetics;large datasets;Location;Maintenance;male;Measures;Messenger RNA;Methods;Modeling;novel;novel strategies;pandemic disease;Paper;Pathogenesis;Pathologic Processes;Peripheral;Phenotype;pressure;prevent;Process;Production;programs;Prophylactic treatment;Proteins;Proviruses;Public Health;Publishing;Regulatory Element;Response Elements;Retroviridae;rev Genes;RNA Binding;RNA Splicing;Role;sexual HIV transmission;Sexual Transmission;System;Time;Tissues;Translating;transmission process;Variant;Viral;Viral Antigens;Viral Envelope Gene;Viral Genes;Viral Proteins;viral transmission;Virus;Virus Latency;Virus Replication;Women's study

PROJECT_TITLE: HIV Rev-Rev Response Element Activity Variation in Transmission and Latency


NIH_SPENDING_CATS: Genetics;HIV/AIDS;Human Genome;Infectious Diseases;Methamphetamine;Stimulant Use and Misuse;Substance Misuse

ORG_CITY: LA JOLLA

ORG_DEPT: PEDIATRICS

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

ORG_STATE: CA

PHR: PROJECT NARRATIVE N6,2’-O-dimethyladenosine (m6Am) is an abundant RNA modification located adjacent to the 5’-end of mRNA 7-methylguanosine (m7G) cap structure that can have a major influence on gene expression of the transcriptome regulating immunity and host-virus interactions. This project will define how HIV infections reprogram host epitranscriptomes in the presence and absence of methamphetamine to cause immune dysfunctions. Results of the proposed studies would provide insight into new mechanisms and targets for developing innovative approaches to eradicate or cure HIV infection.

PI_NAMEs: RANA, TARIQ M (contact)

PROGRAM_OFFICER_NAME: MCDONALD, DAVID JOSEPH

PROJECT_TERMS: 2019-nCoV;7-methylguanosine;Address;Adenosine;Affect;Behavioral;Biochemical;Biological;Brain;CD4 Positive T Lymphocytes;Cells;Complex;Disease;Enzymes;epitranscriptome;epitranscriptomics;Flaviviridae;Gene Expression;Genes;Genetic Transcription;Genome;HIV;HIV Infections;HIV-1;HIV/AIDS;Human;Immune;immune function;Immune response;Immune System Diseases;Immunity;Immunologics;In Vitro;in vivo;Infection;innovation;insight;Life Cycle Stages;Macrophage;Maps;Mass Spectrum Analysis;Messenger RNA;Methamphetamine;methamphetamine exposure;methamphetamine use;Methods;methyl group;Methylation;methylome;Methyltransferase;Modeling;Modification;Molecular;Neurocognitive;novel strategies;Nucleotides;pathogen;Pathogenesis;Pathway interactions;Patients;Pharmaceutical Preparations;Phase;Phosphorylation;Play;Positioning Attribute;Process;programs;Publications;Publishing;Rana;Regulation;Reporting;RNA;RNA metabolism;RNA Splicing;RNA Viruses;Role;Structure;substance use;success;T-Lymphocyte;Transcript;transcription factor;Transcriptional Regulation;transcriptome;Translational Regulation;Translations;Viral;Viral Pathogenesis;viral RNA;Virus;Virus Diseases;virus host interaction;Virus Replication

PROJECT_TITLE: Role of PCIF1 in Regulating Host-HIV interactions


NIH_SPENDING_CATS: Biotechnology;HIV/AIDS;Immunization;Infectious Diseases;Prevention;Vaccine Related;Vaccine Related - AIDS;Women's Health Research

ORG_CITY: ROCHESTER

ORG_NAME: MAYO CLINIC ROCHESTER

ORG_STATE: MN

PHR: Narrative This project will work to developing more effective HIV-1 vaccines that better repel the virus at its site of entry into the body. Proof of concept in this study will allow these approaches to be tested and translated to protect women and men from HIV-1 exposure.

PI_NAMEs: BARRY, MICHAEL A (contact)

PROGRAM_OFFICER_NAME: DANG, QUE

PROJECT_TERMS: 2019-nCoV;Address;Adenovirus Infections;Adenoviruses;Adjuvant;Animals;Antibodies;Antibody Response;Antigens;Automobile Driving;Benchmarking;Body Weight;booster vaccine;Cartoons;Cells;Colon;Colorectal;combat;COVID-19 pandemic;COVID-19 vaccine;cross immunity;Data;Defect;Distant;DNA;Event;Exposure to;female reproductive tract;Gender Identity;Genes;HIV;HIV vaccine;HIV-1;HIV-1 vaccine;Human;Immune;Immune response;Immunization;Immunize;improved;Infection;Infectious Agent;Inferior;Intramuscular;Intravaginal Administration;Kinetics;Lung;Macaca;Macaca mulatta;Mediating;men;Messenger RNA;Modeling;Mucosal Immune Responses;mucosal site;mucosal vaccine;Mucous Membrane;Oral;pathogen;penis;preservation;prevent;Production;Proteins;recruit;Rectum;Reproducibility;response;Risk;RNA vaccine;Route;Saliva;SARS-CoV-2 spike protein;sexual identity;simian human immunodeficiency virus;Site;SIV;Surface;Testing;Time;Transgenes;Translating;Vaccinated;Vaccination;Vaccine Antigen;vaccine delivery;Vaccines;Vagina;Viral;Viral load measurement;Viral Load result;Virion;Virus;Woman;Work

PROJECT_TITLE: Pushing HIV-1 Vaccine Protection to the Mucosal Barrier

STUDY_SECTION: HIVD

STUDY_SECTION_NAME: HIV Immunopathogenesis and Vaccine Development Study Section[HIVD]


ADMINISTERING_IC: CA

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Clinical Research;Digestive Diseases;Immunotherapy;Orphan Drug;Pancreatic Cancer;Precision Medicine;Rare Diseases

ORG_CITY: HOUSTON

ORG_NAME: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON

ORG_STATE: TX

PHR: Narrative Every tumor is biologically unique. Moving from “one-size-fits-all” to personalized medicine in cancer, we need to develop novel platforms to help us improve our understanding of cellular characterizations of individual’s cancer biology and therapeutics. In this project we will develop a personalized ex vivo platform including individual’s cancerous epithelium and the tumor microenvironment. We will show the utility of our system for testing conventional and novel therapeutics. The patient-specific drug response assay technology has the potential to inform the way treatment decisions are made within the context of pancreatic cancer and perhaps other complex solid tumors.

PI_NAMEs: BISHEHSARI, FARAZ  (contact)

PROGRAM_OFFICER_NAME: CHEN, WEIWEI

PROJECT_TERMS: 3-Dimensional;Adjuvant;Antineoplastic Agents;Basic Science;Biological Assay;Cancer Biology;cancer immunotherapy;Cancer Patient;cancer therapy;cancer type;Cancerous;CD8-Positive T-Lymphocytes;Cell Communication;Cell Differentiation process;cell type;Cells;Characteristics;chemotherapy;Clinical;Clinical Trials;cohort;Complex;conventional therapy;Decision Making;design;Devices;Disease Progression;Drug Delivery Systems;drug development;drug efficacy;Drug Modelings;Drug Targeting;drug testing;Elements;Endothelium;Environment;Epithelium;experimental study;Failure;Fibroblasts;Fibrosis;functional outcomes;Genes;Goals;Human;Immune;Immunotherapy;improved;in vivo;Individual;individual response;individualized medicine;innovation;Interruption;Macrophage;Malignant Breast Neoplasm;Malignant neoplasm of pancreas;Malignant Neoplasms;microfluidic technology;Modeling;Molecular;molecular modeling;Molecular Profiling;next generation;novel;novel therapeutics;Organ;organ on a chip;Organoids;Outcome;pancreatic cancer model;Pancreatic Ductal Adenocarcinoma;pancreatic stellate cell;Pathogenicity;Pathology;Pathway interactions;patient subsets;Patient-Focused Outcomes;Patients;personalized medicine;personalized strategies;Pharmaceutical Preparations;Phenotype;pre-clinical;Prediction of Response to Therapy;protein expression;real time monitoring;research and development;Resistance;response;Role;Series;Solid Neoplasm;Source;stellate cell;stem cells;Survival Rate;System;T-Lymphocyte;targeted treatment;Technology;Testing;Therapeutic;therapy resistant;Tissues;treatment response;tumor;tumor behavior;Tumor Immunity;tumor microenvironment;tumor progression;Tumor Promotion;Vascularization

PROJECT_TITLE: Personalized Organoid-Chip Model For Drug Testing in Pancreatic Cancer

STUDY_SECTION: DMP

STUDY_SECTION_NAME: Drug Discovery and Molecular Pharmacology Study Section[DMP]


FUNDING_MECHANISM: RESEARCH CENTERS

NIH_SPENDING_CATS: Clinical Research;HIV/AIDS;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Infectious Diseases;Prevention

ORG_CITY: SAN FRANCISCO

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

PHR: PROJECT NARRATIVE The restructured UCSF-Bay Area CFAR is dedicated to promoting multidisciplinary research addressing cutting-edge questions in HIV/AIDS biology, treatment, and prevention. This approach from UCSF has led to breakthrough discoveries advancing patient care and providing new approaches to curbing the HIV pandemic both locally and internationally. CFAR is also committed to supporting the next generation of HIV researchers, international research, health equity, and community engagement, all of which are critical for truly ending the HIV epidemic.

PI_NAMEs: GANDHI, MONICA  (contact)

PROGRAM_OFFICER_NAME: REFSLAND, ERIC WILLIAM

PROJECT_TERMS: Acquired Immunodeficiency Syndrome;Address;Adherence;Advocacy;Area;Basic Science;Behavior;Behavioral Research;biobehavior;Bioinformatics;Biological Markers;Biological Specimen Banks;Biology;Biometry;career;career development;Cities;Clinic;Clinical;clinical care;Clinical Research;co-infection;cohort;Collaborations;Communication;Communities;community engagement;comorbidity;computerized data processing;Dedications;Development;Educational workshop;Epidemic;Evaluation;Event;experience;Fostering;Foundations;functional genomics;Goals;Grant;health equity;HIV;HIV/AIDS;Housing;Immunology;implementation science;improved;Inflammation;Infusion procedures;innovation;Institution;Interdisciplinary Study;International;intersectionality;Laboratories;Leadership;Measures;meetings;Mentors;Methods;minority investigator;Monitor;multidimensional data;multidisciplinary;Multiomic Data;Names;National Institute of Allergy and Infectious Disease;next generation;novel;novel strategies;Outcome;pandemic disease;Participant;Pathogenesis;Patient Care;Pharmacology;Positioning Attribute;pre-exposure prophylaxis;Prevention;Productivity;programs;Prospective cohort;referral services;Research;Research Personnel;Resources;response;Risk;social;Specimen Handling;structural determinants;structural health determinants;substance use;Training;Translational Research;Underrepresented Minority;United States National Institutes of Health;Visualization;Vulnerable Populations;ward;Work;working group

PROJECT_TITLE: UCSF-Bay Area Center for AIDS Research


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Clinical Research;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Precision Medicine;Racial and Ethnic Minority Health Research

ORG_CITY: STANFORD

ORG_DEPT: ANESTHESIOLOGY

ORG_NAME: STANFORD UNIVERSITY

PHR: PROJECT NARRATIVE: Nearly 40% of descendants from East Asia possess a genetic variant severely limiting their ability to metabolize reactive aldehydes. In addition, several other genetic differences in the lipid peroxidation pathway also occur in Asians which may impact organ injury, particularly during surgery. This project will develop tools in the basic science laboratory to better understand how genetic differences in the lipid peroxidation pathway may impact organ damage and translate these strategies to monitor and reduce organ damage in humans undergoing surgery.

PI_NAMEs: GROSS, ERIC RICHARD (contact)

PROGRAM_OFFICER_NAME: JUSTINOVA, ZUZANA

PROJECT_TERMS: Aldehydes;Analgesics;Anesthesia procedures;Anesthetics;Asian Americans;Asian population;Basic Science;Biological;Biological Assay;Caring;Cause of Death;cell injury;Ethnic Origin;Far East;Functional disorder;Genetic;Genetic study;genetic variant;Health Care Costs;Human;Human Genetics;improved;insight;Knock-in Mouse;Laboratories;Lipid Peroxidation;Medical;Metabolism;Methods;Monitor;mortality;mouse model;novel;novel strategies;Operative Surgical Procedures;Organ;organ injury;Other Genetics;Pathway interactions;Persons;Phenotype;Population;precision medicine;programs;Quality of Care;Rodent;Time;tool;Translating;treatment strategy;TRP channel;United States

PROJECT_TITLE: Precision medicine for Asian Americans requiring anesthesia

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CB-T(55)R]


ADMINISTERING_IC: NS

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

ORG_CITY: CHICAGO

ORG_DEPT: PHYSIOLOGY

ORG_NAME: NORTHWESTERN UNIVERSITY AT CHICAGO

ORG_STATE: IL

PHR: Narrative: Parkinson’s disease (PD) is the second most common neurodegenerative disease in world, but current symptomatic therapies are of limited value and have unwanted side-effects. Through the use of new genetic tools to manipulate and monitor the function of neurons in the brain regions responsible for PD, we have found that a particular type of neuron plays a pivotal role in both the core motor symptoms of PD and dyskinetic side-effects of the gold standard treatment for PD – levodopa. The proposed studies will build upon this discovery to forge a better understanding the cellular and molecular mechanisms underlying PD in the hope that this will lead us to new symptomatic therapies that are more effective and less burdened by side-effects.

PI_NAMEs: SURMEIER, DALTON JAMES (contact)

PROGRAM_OFFICER_NAME: SIEBER, BETH-ANNE

PROJECT_TERMS: Acetylcholine;Age;Behavior;Behavioral;Brain region;cell type;cholinergic;Collection;connectome;Corpus striatum structure;Data;Development;Disease;Dopamine;Dose;Dyskinetic syndrome;Electrophysiology (science);Event Horizon;Evolution;FDA approved;forging;Foundations;Functional disorder;Genetic;Genetic Suppression;Grant;grasp;Image;Incidence;interest;Interneuron function;Interneurons;L-DOPA induced dyskinesia;Laser Scanning Microscopy;Levodopa;Medical;Modeling;Molecular;Monitor;motor symptom;mouse model;Movement;Muscarinic Acetylcholine Receptor;Muscarinics;Neurodegenerative Disorders;Neurons;neurosurgery;novel;novel therapeutics;optical sensor;optogenetics;Oral;Parkinson Disease;Pathway interactions;Patients;Pharmaceutical Preparations;pharmacologic;Play;Population;Potassium Channel;Property;Quality of life;Risk Factors;Rodent Model;Role;Severities;side effect;Signal Transduction;standard care;Substance P;Symptoms;Synapses;Synaptic plasticity;Testing;Therapeutic;Thinking;tool;Translating;translational goal;treatment strategy;two-photon;Work

PROJECT_TITLE: Dopaminergic and Muscarinic Signaling in the Striatum


FUNDING_MECHANISM: SBIR-STTR RPGS

NIH_SPENDING_CATS: Biotechnology;Gene Therapy;Genetics

ORG_CITY: Chapel Hill

ORG_NAME: NEUROGT, INC.

ORG_STATE: NC

PHR: Project Narrative: Gene therapy products using adeno-associated-virus (AAV) vector have shown to be promising for treating diseases in humans. However, AAV is widespread in humans with high prevalence of anti-AAV antibodies in human population, and currently, only individuals who do not have anti-AAV antibodies are eligible for AAV gene therapy treatment. This proposal is to develop an effective antibody-degrading protein product to transiently remove the pre-existing anti-AAV antibodies for AAV gene therapy, towards clinical application and commercialization.

PI_NAMEs: MCCARTY, DOUGLAS M (contact)

PROGRAM_OFFICER_NAME: MINNICOZZI, MICHAEL

PROJECT_TERMS: Address;adeno-associated viral vector;Adverse event;Animal Model;Animals;Antibodies;Applications Grants;Biodistribution;Blocking Antibodies;Blood specimen;cell growth;Cells;clinical application;Clinical Chemistry;Clinical Trials;clinically relevant;Codon Nucleotides;commercialization;Development;Disease;Dose;Dose Limiting;efficacy evaluation;Eligibility Determination;Enzymes;Face;Galium;Gene Delivery;gene replacement therapy;gene therapy;Genetic Diseases;Goals;Growth;Hematology;High Prevalence;Histopathology;Human;Immune response;Immunoglobulin G;Individual;Infusion procedures;Injections;Life;manufacturing scale-up;Modeling;mouse model;Mus;Mutation;Oryctolagus cuniculus;Patients;Phase;phase 1 study;phase 2 study;Population;preclinical study;Primates;Procedures;Production;protein expression;protein purification;Proteins;Recombinant adeno-associated virus (rAAV);Regimen;Safety;safety testing;Sheep;Small Business Innovation Research Grant;Streptococcus;Temperature;Testing;Therapeutic;Therapy Clinical Trials;Time;Tissue Sample;tool;Toxic effect;Toxicology;transduction efficiency;Translations;vector;Viral;Viral Antibodies;Viral Genes;Viral Vector

PROJECT_TITLE: Protein depleting pre-existing antibodies for viral gene therapy


ADMINISTERING_IC: EY

IC_NAME: NATIONAL EYE INSTITUTE

NIH_SPENDING_CATS: Aging;Autoimmune Disease;Bioengineering;Dental, Oral, and Craniofacial Disease;Digestive Diseases;Eye Disease and Disorders of Vision;Immunotherapy;Nanotechnology;Orphan Drug;Rare Diseases;Women's Health Research

ORG_CITY: Los Angeles

ORG_DEPT: OPHTHALMOLOGY

ORG_NAME: UNIVERSITY OF SOUTHERN CALIFORNIA

PHR: Project Narrative (Parent Award) Sjögren's syndrome is an an autoimmune disease associated with local inflammation and decreased function of lacrimal and salivary glands, as well as systemic inflammation of many other internal organs. Treatment options are limited, possibly because approved treatments do not achieve immunomodulation at both local glandular and systemic sites, both of which sustain disease. Capitalizing on the novel properties of elastin-like polypeptides, we develop distinct strategies to more effectively treat local, glandular and systemic symptoms with immunomodulatory agents, and then explore their efficacy and toxicity in combination, all in murine models of the disease.

PI_NAMEs: HAMM-ALVAREZ, SARAH F (contact);MACKAY, JOHN ANDREW

PROGRAM_OFFICER_NAME: MCKIE, GEORGE ANN

PROJECT_TERMS: Affect;Affinity;American;Antibodies;Artificial Tears;Autoantibodies;Autoimmune;Autoimmune Diseases;B-Cell Lymphomas;belimumab;Binding;Biodegradation;Biodistribution;Biological Availability;Biological Products;Cell Adhesion Molecules;Cells;Chimeric Proteins;chromosome 22 supernumerary marker;Clinical;clinically relevant;Combined Modality Therapy;Complex;Cornea;Cyclosporine;cytokine;design;Development;diabetic;Disease;disease model;Dose;Drug Carriers;Drug Kinetics;Dry Eye Syndromes;effective therapy;efficacy evaluation;Elastin;elastin-binding protein;Engineering;Epithelial Cells;Epithelium;Exhibits;extracellular;Extracellular Domain;Eye;eye dryness;Fatigue;Female;Flow Cytometry;Fluorescein;Formulation;Histologic;Histology;Hydroxychloroquine;IL17 gene;immune modulating agents;Immune system;immunoregulation;Immunosuppression;Immunosuppressive Agents;improved;in vitro activity;Inbred NOD Mice;Individual;Infiltration;Inflammation;Injections;innovation;Intuition;Lacrimal gland structure;Link;Liquid substance;Local Therapy;Localized Disease;loss of function;male;Measurement;Measures;Methotrexate;Modeling;Molecular Target;mouse model;nanomedicine;nanoparticle;nanopolymer;Non obese;NOR Mouse;novel;novel strategies;novel therapeutics;ocular surface;Oral;Organ;parent project;Pathogenesis;Patients;Peptides;Pharmaceutical Preparations;Polymers;polypeptide;Production;Property;Proteins;receptor;Regimen;Risk;rituximab;Saliva;Salivary;Salivary Glands;Serum;sex as a biological variable;Sialadenitis;Sirolimus;Site;Sjogren's Syndrome;Stains;subcutaneous;Submandibular gland;success;symptom management;Symptoms;Systemic disease;systemic inflammatory response;Systemic Therapy;Tacrolimus Binding Protein 1A;Tacrolimus Binding Proteins;Technology;Testing;Therapeutic;Time;Tissue imaging;tocilizumab;Topical application;Toxic effect;Transition Temperature;Treatment Efficacy;Treatment Protocols;Visceral;Xerostomia

PROJECT_TITLE: Protein-polymer nanomedicine for Sjogren's Syndrome


FUNDING_MECHANISM: NON SBIR/STTR CONTRACTS

ORG_CITY: BETHESDA

ORG_NAME: TECHNICAL RESOURCES INTERNATIONAL, INC.

ORG_STATE: MD

PI_NAMEs: HEREDIA, ELIZABETH  (contact)

PROJECT_TERMS: Clinical Research;National Institute of Allergy and Infectious Disease;Regulatory Affairs;Research Activity;Research Support

PROJECT_TITLE: Regulatory Affairs Support


ADMINISTERING_IC: MH

IC_NAME: NATIONAL INSTITUTE OF MENTAL HEALTH

NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Depression;Dissemination and Implementation Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Major Depressive Disorder;Maternal Health;Maternal Morbidity and Mortality;Mental Health;Mental Illness;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Pregnancy;Preterm, Low Birth Weight and Health of the Newborn;Prevention;Racial and Ethnic Minority Health Research;Serious Mental Illness;Social Determinants of Health;Women's Health Research

ORG_CITY: SAINT LOUIS

ORG_DEPT: OBSTETRICS & GYNECOLOGY

ORG_NAME: WASHINGTON UNIVERSITY

ORG_STATE: MO

PHR: Project Narrative This study will provide high-quality, representative data on the capacity of Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care (EleVATE GC) to reduce perintal depression, preterm birth, and low birthweight in African-American women. If findings from this study indicate that EleVATE GC is feasible and effective, this model could be implemented nationwide to help achieve mental and obstetric health parity for low-income women of color in the United States.

PI_NAMEs: CARTER, EBONY BOYCE;LENZE, SHANNON NICOLE (contact)

PROGRAM_OFFICER_NAME: MAVANDADI, SHAHRZAD

PROJECT_TERMS: Address;Adverse event;adverse pregnancy outcome;Affect;African American Women;antepartum depression;Anxiety;Anxiety Disorders;Appointment;Area;behavioral health intervention;Birth Rate;Caring;Chronic Disease;Clinic;Collaborations;Data;Diagnosis;Discipline of obstetrics;Disease Management;disparity reduction;effectiveness evaluation;effectiveness testing;effectiveness-implementation RCT;Enrollment;Equity;Event;evidence base;experience;Exposure to;Face;Health;high risk;High Risk Woman;implementation context;implementation determinants;implementation strategy;improved;improved outcome;Individual;Insurance Coverage;Intervention;Life;Low Birth Weight Infant;Low income;maternal risk;Medicaid;Mental Depression;Mental Health;Mental Health Services;Minority Women;Modeling;Mood Disorders;Neonatal;novel;Outcome;outcome disparities;parity;Patients;Perinatal;peripartum depression;pilot trial;Population;Postpartum Depression;Practical Robust Implementation and Sustainability Model;Pregnancy;Pregnant Women;Premature Birth;prenatal;Prenatal care;primary outcome;programs;Provider;Psyche structure;psychological distress;Psychosocial Stress;racism;Recording of previous events;Research Personnel;Resources;Risk;secondary outcome;Services;Site;Stigmatization;Stress;System;Testing;therapy design;Time;Trauma;trial comparing;Underserved Population;United States;Voice;White Women;Woman;women of color


ED_INST_TYPE: SCHOOLS OF DENTISTRY/ORAL HYGN

NIH_SPENDING_CATS: Biotechnology;Cancer;Neuroblastoma;Neurosciences;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: RICHMOND

ORG_DEPT: DENTISTRY

ORG_NAME: VIRGINIA COMMONWEALTH UNIVERSITY

PHR: Project Narrative The oncogenic transcription factor MYCN drives a subset of neuroblastoma tumors which is deadly in half the cases despite protracted and intense therapy including polychemotherapy and immunotherapy (anti-GD2 therapy). As MYCN remains undruggable, finding synthetic lethal relationships that may result in new treatments is one of the “holy grails” of pediatric cancer therapy. In this grant proposal, we provide evidence that amplified MYCN orchestrates a complex and intricate re-wiring of the neuroblastoma cell to 1) increase iron metabolism, 2) increase cysteine and selenocysteine biosynthesis to counteract reactive oxygen species created from iron metabolism-related Fenton reactions and 3) increase synthesis of pantothenate kinase 3 (PANK3) to subsequently increase coA levels; the result of which is the creation of a synthetic lethality and therapeutic vulnerability to ferroptosis induction which we aim to explore, clarify and translate to new therapeutic options for this recalcitrant pediatric tumor.

PI_NAMEs: FABER, ANTHONY CHARLES (contact);OLZMANN, JAMES A

PROGRAM_OFFICER_NAME: FORRY, SUZANNE L

PROJECT_TERMS: aged;Anabolism;Antioxidants;Apoptosis;Apoptotic;Applications Grants;BCL1 Oncogene;BCL2 gene;Biological;cancer cell;cancer therapy;Cell Culture Techniques;Cell Death;Cell Line;Cells;Chemicals;Child;Clinic;Clinical;Clinical Investigator;Coenzyme A;combat;Combination Drug Therapy;Combined Modality Therapy;Complex;Cysteine;Dependence;Disease;disorder risk;Drug Metabolic Detoxication;Drug Targeting;experimental study;FDA approved;Genetic;Genetic Screening;Genomics;Glutathione;glutathione peroxidase;Goals;Grant;Growth;high risk;Immunotherapy;improved;in vivo Model;inhibitor;Iron;iron metabolism;kinase inhibitor;Malignant Childhood Neoplasm;Malignant Neoplasms;Mediating;Modeling;mouse model;Mus;MYCN gene;Nature;Neuroblastoma;neuroblastoma cell;new combination therapies;novel;novel therapeutics;Oncogenes;Oncogenic;Oxygen;Pantothenate kinase;Pantothenic Acid;Pathway interactions;patient derived xenograft model;Patients;Pediatric Neoplasm;Peroxidases;Pharmacologic Substance;Phenotype;Phosphotransferases;pre-clinical;Production;programs;Proliferating;Reaction;Reactive Oxygen Species;Refractory;Relapse;Research Design;Resistance;resistance mechanism;response;screening;Selenocysteine;selenoprotein;Stress;Testing;Therapeutic;Time;transcription factor;Translating;translational medicine;Translational Research;treatment response;tumor;Work

PROJECT_TITLE: MYCN drives a ferroptotic vulnerability in neuroblastoma


ORG_CITY: RANCHO SANTA FE

ORG_NAME: RESOLUTE SCIENCE, INC.

PHR: PROJECT NARRATIVE Soft tissues sarcomas (STS) is a broad term for multiple subtypes of cancer that start in soft tissues. There is currently no unifying treatment for STS subtypes beyond surgery, chemotherapy, and radiation. Resolute Science Inc. is developing novel STS therapy by using tumor-associated macrophages (TAMs) to process and deliver anti-cancer agents to solid tumors.

PI_NAMEs: BARNETT, FAITH H (contact)

PROGRAM_OFFICER_NAME: EVANS, GREGORY

PROJECT_TERMS: absorption;Adolescent;Adult;American Cancer Society;anti-cancer;Antibodies;Antibody-drug conjugates;Antineoplastic Agents;Behavior;Biological Assay;Body Weight Changes;Body Weight decreased;Bypass;cancer cell;cancer subtypes;cancer therapy;cancer type;Canis familiaris;Cell Line;Cells;Cessation of life;chemical substitution;chemotherapy;Child;Clinic;Clinical;clinical development;Clinical Research;cost;Data;Disease;dosage;Dose;Doxorubicin;Drug Design;effectiveness evaluation;efficacy study;Ewings sarcoma;Excretory function;Female;Goals;Good Manufacturing Process;Guidelines;Histologic;Human;Ifosfamide;improved;innovation;Insurance Carriers;Investigational Drugs;Lead;leiomyosarcoma;Ligand Binding;Ligands;Liquid Chromatography;liver function;Macrophage;male;Malignant Fibrous Histiocytoma;Malignant Neoplasms;manufacture;Mass Spectrum Analysis;Maximum Tolerated Dose;Measures;Metabolism;Methodology;Methods;Modeling;molecular subtypes;mouse model;Mus;novel;novel strategies;Nude Mice;Oncology;Operative Surgical Procedures;patient derived xenograft model;Patients;pharmacokinetics and pharmacodynamics;Pharmacotherapy;Phase;pre-clinical;pre-Investigational New Drug meeting;Price;Process;programs;Property;Radiation;Rattus;Receptor Cell;Recovery;Renal function;research clinical testing;Resistance;response;Rodent;Sarcoma;Science;Small Business Innovation Research Grant;soft tissue;Soft tissue sarcoma;Solid Neoplasm;subcutaneous;success;Survival Rate;synovial sarcoma;targeted treatment;Therapeutic;therapeutic target;Toxic effect;Toxicokinetics;Toxicology;Toxin;Treatment outcome;tumor;tumor heterogeneity;Tumor-associated macrophages;United States;Validation;validation studies;Vertebral column;Work

PROJECT_TITLE: Targeting Macrophages to Treat Soft Tissue Sarcomas


ADMINISTERING_IC: EB

ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

IC_NAME: NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING

NIH_SPENDING_CATS: Assistive Technology;Bioengineering;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurosciences;Racial and Ethnic Minority Health Research

ORG_CITY: BALTIMORE

ORG_DEPT: BIOMEDICAL ENGINEERING

ORG_NAME: JOHNS HOPKINS UNIVERSITY

PHR: NeuroTech Harbor (NTH) led by Johns Hopkins and Howard Universities will gather innovators, expert mentors, and resource providers to accelerate the development of highly promising solutions to improve neurological health for all. To address the lack of women and under-represented minority innovators, it will create the nation's first incubator ecosystem with an Equitech philosophy - the belief that diversity of teams, leadership, and perspectives is a force multiplier to fuel innovation producing solutions accessible to all communities.

PI_NAMEs: ETIENNE-CUMMINGS, RALPH ;MANAYE, KEBRETEN F;NWULIA, EVARISTUS A;SARMA, SRIDEVI V. (contact);THAKOR, NITISH VYOMESH;YAZDI, YOUSEPH

PROGRAM_OFFICER_NAME: WOLFSON, MICHAEL

PROJECT_TITLE: NeuroTech Harbor: Our nation's first equitech ecosystem for neuromedical technologies


NIH_SPENDING_CATS: Assistive Technology;Bioengineering;Eye Disease and Disorders of Vision;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurosciences;Racial and Ethnic Minority Health Research


NIH_SPENDING_CATS: Bioengineering;Neurosciences

ORG_CITY: BOSTON

ORG_NAME: MASSACHUSETTS GENERAL HOSPITAL

ORG_STATE: MA

PHR: Project Narrative The goal of the Center for Innovative NeuroTech Advancement (CINTA) is to rapidly transform emerging technologies into commercially viable, clinically focused solutions for disorders of the nervous system as a hub under the NIH Blueprint MedTech: Incubator Hubs program. CINTA will support the advancement of neurotechnology solutions by adapting and improving upon the proven model that CIMIT developed and implemented for RADx Tech to accelerate promising neurotechnologies that address critical areas of unmet needs in the diagnosis and treatment of nervous system disorders to human-grade prototypes. CINTA plans to find, fund, facilitate, and accelerate 15 projects per year through this program.

PI_NAMEs: BONATO, PAOLO ;SCHACHTER, STEVEN C. (contact)

PROJECT_TERMS: Acceleration;Address;Area;Clinical;Collaborations;commercialization;Committee Members;Communities;Companions;Complex;Development;Diagnosis;Emerging Technologies;Ensure;Environment;equity, diversity, and inclusion;Evaluation;experience;Funding;Goals;Health Technology;Healthcare;Human;improved;Incubators;Infrastructure;innovation;Institution;interest;International;Investments;Laboratories;Leadership;manufacture;Medical;Medicine;Modeling;multidisciplinary;Needs Assessment;Nervous System Disorder;neurological rehabilitation;neurotechnology;Outcome;outreach;Performance;Process;programs;prototype;RADx Tech;Research;Research Personnel;Resources;Risk;Science;sharing platform;success;technological innovation;Technology;tool development;Training;Translational Research;United States National Institutes of Health;virtual technology;web site

PROJECT_TITLE: Center for Innovative NeuroTech Advancement - CINTA


ADMINISTERING_IC: AT

ED_INST_TYPE: SCH ALLIED HEALTH PROFESSIONS

IC_NAME: NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH

NIH_SPENDING_CATS: Chronic Pain;Complementary and Integrative Health;Natural Products;Neurosciences;Pain Research

ORG_CITY: RICHARDSON

ORG_DEPT: NEUROSCIENCES

ORG_NAME: UNIVERSITY OF TEXAS DALLAS

PHR: PROJECT NARRATIVE  Over the past 25 years, the search for novel analgesics has had only a few successes and many failures; some of these failures have occurred through an overreliance on screening of compounds in rodent models of pain or physiology that fail to translate to homo sapiens. In this proposal, we take a target agnostic but human centric approach to discover novel natural product fractions with potential to induce analgesia through peripheral nociceptors. Natural product fractions from the National Cancer Institutes Natural Products Repository will be screened for analgesic activity in human “nociceptor” cells using multi-electrode array technology.

PI_NAMEs: DUSSOR, GREGORY O;KOLBER, BENEDICT J (contact);PANCRAZIO, JOSEPH J.

PROGRAM_OFFICER_NAME: CHEN, WEN G

PROJECT_TERMS: Absence of pain sensation;Action Potentials;Acute Pain;Address;Afferent Neurons;Agonist;Analgesics;Anatomy;Animals;antagonist;Baclofen;Basic Science;Behavior;Biochemical;Biological Assay;Biology;Capsaicin;Cell Physiology;Cells;Chili Pepper;chronic pain;cytokine;Data;Development;efficacy study;Electrodes;Electrophysiology (science);Ethics;Evaluation;Event;Failure;Genes;Heterogeneity;high throughput screening;Home;Homo sapiens;Human;human induced pluripotent stem cells;In Vitro;in vivo;Inflammatory;inflammatory pain;inhibitor;innovation;Interleukin 6 Receptor;Interleukin-6;Libraries;marine organism;Measures;Methods;Modeling;Modernization;Molecular Target;mouse model;multi-electrode arrays;Mus;National Cancer Institute;Natural Products;Natural Source;Neurons;Nociception;Nociceptors;novel;Operative Surgical Procedures;opioid epidemic;Organ Donor;Organism;Pain;pain model;Paper;patch clamp;Patients;Peripheral;pharmacologic;Pharmacology;pharmacophore;Phase;Phenotype;Physiological;Physiology;Plants;pre-clinical;Process Assessment;Proteins;Publishing;Rattus;repository;Research;Rodent;Rodent Model;screening;single cell sequencing;Sorting;Source;Speed;Spinal Ganglia;Stimulus;success;Technology;Testing;Therapeutic;tool;transcriptome;transcriptome sequencing;transcriptomics;Translating;Translations;TRPV1 gene

PROJECT_TITLE: High content analgesic screening from human nociceptors

STUDY_SECTION: NSS

STUDY_SECTION_NAME: NSS


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Genetics;Mental Health;Mental Illness;Neurosciences;Schizophrenia

PHR: Narrative While current pharmacological treatments with antipsychotics have beneficial effects on the positive symptoms of schizophrenia, they lack efficacy against cognitive symptoms, which are critical predictors of long-term clinical outcomes. We hypothesize that a shift from inhibitory to excitatory GABAA current in the prefrontal cortex of adult animals is a critical pathogenic mechanism shared by multiple genetic models of schizophrenia representing diverse etiologies including copy number variants (16p11.2 duplication), rare variants (TRIO+/-), and common variants (Cacna1C+/-), and that pharmacological correction of this shift rescues cognitive performance in these animals.

PI_NAMEs: MARTINA, MARCO  (contact)

PROGRAM_OFFICER_NAME: HUPALO, SOFIYA

PROJECT_TERMS: 16p11.2;Acute;Adult;Affect;Animals;antagonist;Antipsychotic Agents;Behavior assessment;Behavioral;Biological Assay;Biology;Brain;Bumetanide;Cations;Cells;Chloride Ion;Chlorides;Chronic;Clinical;Clinical Trials;Cognitive;Cognitive deficits;cognitive function;cognitive performance;cognitive task;cognitive testing;Collaborations;Copy Number Polymorphism;Data;density;disease model;Electrophysiology (science);Etiology;experimental study;FDA approved;Female;Functional disorder;gamma-Aminobutyric Acid;Gene Expression;Genes;Genetic;Genetic Diseases;Genetic Models;Genetic Risk;genetic variant;hippocampal pyramidal neuron;Human;Impaired cognition;In Situ Hybridization;in vivo;Incidence;Infusion procedures;inhibitor;male;mature animal;Medial;Mediating;Mental disorders;Modeling;Morphology;mouse model;Mus;Mutation;Neurobehavioral Manifestations;Neurodevelopmental Disorder;Neuroglia;Neurons;novel;object recognition;Outcome;patch clamp;Pathogenicity;patient subsets;Perforation;Performance;Pharmaceutical Preparations;pharmacologic;Pharmacological Treatment;Phencyclidine;Phenotype;Physiological;preclinical study;Prefrontal Cortex;Psychiatry;Pyramidal Cells;rare variant;Reversal Learning;Rodent Model;Safety;Schizophrenia;schizophrenia risk;Short-Term Memory;Signal Transduction;Slice;social;social deficits;Social Interaction;symporter;Symptoms;synaptic inhibition;System;Testing;tool;Transcript;Variant;Vertebral column;Viral;Wild Type Mouse

PROJECT_TITLE: NKCC1-KCC2 system modulation in rodent models relevant for psychiatric disorders

STUDY_SECTION: PMDA

STUDY_SECTION_NAME: Pathophysiological Basis of Mental Disorders and Addictions Study Section[PMDA]


ADMINISTERING_IC: OD

IC_NAME: OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH

NIH_SPENDING_CATS: Clinical Research;Conditions Affecting the Embryonic and Fetal Periods;Endocrine Disruptors;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Pregnancy;Prevention;Rural Health;Social Determinants of Health

ORG_CITY: EAST LANSING

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES

ORG_STATE: MI

PHR: Project Narrative Many important problems in child health and development may result from a mother’s environment during pregnancy. We are a coalition of scientists in Michigan who plan to 1) continue collecting information from the 1,600 families we have already enrolled in the Environmental influences on Child Health Outcomes (ECHO) study; and 2) enroll another 540 families from diverse populations. Working together with other study groups who are part of the national ECHO program, we hope to learn what changes might be made during a woman’s pregnancy that could prevent later problems in child health and development.

PI_NAMEs: BARONE, CHARLES JAMES;ELLIOTT, MICHAEL R.;FUSSMAN, CHRIS ;KERVER, JEAN MARIE (contact);PANETH, NIGEL SEFTON;RUDEN, DOUGLAS M

PROGRAM_OFFICER_NAME: LAESSIG, SUSAN ALISON

PROJECT_TERMS: Acceleration;Advisory Committees;African American;Area;Birth;Body mass index;Chemical Exposure;Child;Child Development;Child Health;Cities;Clinic;cohort;Collaborations;Conceptions;Consent;Data;Data Collection;design;Development;early life adversity;Eligibility Determination;Enrollment;Environment;epigenetic aging;Epigenetic Process;Exposure to;extracellular;Family;Feeding Patterns;follow-up;Follow-Up Studies;Funding;Future;Goals;gut microbiome;Health;Heavy Metals;improved;infancy;Infant;Institution;Iodine;Iron;Leadership;Learning;Left;Live Birth;Location;Maternal and Child Health;Mediator;men;Metabolic;Michigan;Micronutrients;Mothers;National Children's Study;Neighborhoods;neurodevelopment;Nutritional;Obesity;offspring;Outcome;Outcome Study;Paper;Participant;Patient Recruitments;Perinatal Exposure;Phase;phthalates;Plasma;Poly-fluoroalkyl substances;Population Heterogeneity;Positioning Attribute;Pregnancy;Pregnant Women;Premature Birth;prenatal;Prenatal care;prenatal exposure;prevent;programs;Protocols documentation;recruit;Recurrence;Research;Resources;Risk;Rural;Rural Community;rural underserved;Sampling;Sampling Studies;Science;Scientist;Site;sperm cell;stressor;study population;Testing;Visit;Woman;Work;working group;Writing

PROJECT_TITLE: Prenatal Exposures and Child Health Outcomes 2: Increasing ECHO Urban and Rural Diversity

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-EPH-S(50)R]


ORG_CITY: BIRMINGHAM

ORG_NAME: UNIVERSITY OF ALABAMA AT BIRMINGHAM

ORG_STATE: AL

PHR: NARRATIVE Black adolescents and young adults bear a disproportionate burden of both HIV and STI acquisitions, especially in the South. Increased HIV and STI testing is vital to improving overall sexual health for this vulnerable population, however access to HIV and STI testing remains inadequate. We propose to evaluate the implementation of varied HIV and STI testing modalities (i.e., facility based versus at-home testing) and explore the role of syndemics (i.e., mental illness, drug usage, and the social determinants of health) on testing preferences to enhance evidence-based approaches to promote optimal HIV and STI testing options that are feasible and acceptable to HBCU student populations in the South.

PI_NAMEs: CORCORAN, JESSICA LEE;HEFFRON, RENEE A. (contact)

PROGRAM_OFFICER_NAME: SCHOONMAKER, ANNALISE ROSA

PROJECT_TERMS: 19 year old;acceptability and feasibility;Acquired Immunodeficiency Syndrome;Address;Adolescence;Adolescent;Adolescent and Young Adult;adolescent health outcomes;Advocate;Affect;Age;aged;AIDS prevention;Alabama;Area;Award;Black American;Black race;Caring;Chlamydia;Collaborations;college;Communities;community advisory board;community partners;condoms;Data;Diagnosis;Disparity;Disparity population;Drops;Drug usage;Enrollment;Epidemic;epidemic preparedness;evidence base;Feedback;follow-up;Funding;Geography;Goals;Health education;Health Personnel;Health Services;Historically Black Colleges and Universities;HIV;HIV diagnosis;HIV Infections;HIV risk;HIV Seropositivity;home test;Hot Spot;Human immunodeficiency virus test;implementation evaluation;implementation framework;implementation outcomes;Imprisonment;improved;Incidence;Infection;infection burden;infection rate;Interview;Medical History;Mental disorders;Mental Health;Mental Health Services;Modality;Nature;novel;Outpatients;Participant;Persons;Pilot Projects;Population;preference;Prevention;Process;programs;Provider;Punishment;Reach, Effectiveness, Adoption, Implementation, and Maintenance;Recording of previous events;recruit;Reporting;Research Personnel;Risk;Role;Schools;screening;service organization;Services;Severities;Sex Behavior;Sexual Health;sexual risk behavior;Sexually Transmitted Diseases;social health determinants;Spottings;Students;Surveys;syndemic;Testing;testing services;testing uptake;theories;transmission process;United States;university student;Unsafe Sex;uptake;Vulnerable Populations;Work;Youth

PROJECT_TITLE: Exploring Syndemic Factors associated with HIV and STI Testing Preferences Among Students at an HBCU in Alabama


NIH_SPENDING_CATS: Anxiety Disorders;Brain Disorders;Clinical Research;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Human Genome;Mental Health;Mental Illness;Racial and Ethnic Minority Health Research;Serious Mental Illness

ORG_DEPT: PSYCHIATRY

ORG_NAME: BAYLOR COLLEGE OF MEDICINE

PHR: PROJECT NARRATIVE Obsessive-compulsive disorder (OCD) is a neuropsychiatric condition that causes enormous human suffering and cost to society. Our goal is to rapidly learn more about the genetics of this disorder and how genes and environment might act and interact to alter disease risk. We propose to do this by collecting a new, large, ancestrally-diverse and well-phenotyped sample of OCD cases followed by detailed genomic analyses.

PI_NAMEs: STORCH, ERIC A. (contact)

PROGRAM_OFFICER_NAME: PEVSNER, JONATHAN ABRAM

PROJECT_TERMS: Address;Area;Argentina;autism spectrum disorder;Bioethics;Biological;Biology;Bipolar Disorder;Brazil;Chile;Chronic;Clinic;Clinical;cohort;Cohort Studies;Collaborations;Colombia;comorbidity;cost;cost effective;Data;design;Detection;Diagnosis;Dimensions;Disease;disorder risk;Disparity;DNA;Ecuador;Environment;Equity;Etiology;European ancestry;follow-up;Functional disorder;Funding;Future;Genes;Genetic;genetic analysis;genetic architecture;Genetic Diseases;Genetic study;Genome Mappings;genome wide association study;genome-wide;genomic locus;Genomics;Genotype;Goals;health disparity;high risk;Human;improved;Individual;Knowledge;Latin America;Latin American;Latinx;Learning;Linkage Disequilibrium;Maps;Measures;Mental disorders;Mental Health;Meta-Analysis;Mexico;neuropsychiatry;novel;Obsessive-Compulsive Disorder;Online Systems;Outcome;Pathway interactions;Patients;Performance;Phenotype;phenotypic data;polygenic risk score;Population;precision medicine;Prevention strategy;psychiatric genomics;Public Health;recruit;Reduce health disparities;Risk;risk variant;Saliva;Sample Size;Sampling;Schizophrenia;Science;screening;Severities;societal costs;Societies;Specialist;Structure;Symptoms;Testing;Training;Variant;Work;working group

PROJECT_TITLE: 2/2 TRANS-ANCESTRY GENOMIC ANALYSIS OF OBSESSIVE COMPULSIVE DISORDER


FUNDING_MECHANISM: OTHERS

NIH_SPENDING_CATS: Precision Medicine

ORG_DEPT: GENETICS

PHR: No PHR

PI_NAMEs: LEE, BRENDAN ;MURRAY, DEBRA DIANNE (contact);ROSALES, LAURA LEAL

PROGRAM_OFFICER_NAME: MCMASTER, SYDNEY JAYD

PROJECT_TITLE: ALL OF US EVENINGS WITH GENETICS RESEARCH EDUCATION PROGRAM


NIH_SPENDING_CATS: Biotechnology;Machine Learning and Artificial Intelligence

ORG_CITY: Newark

ORG_DEPT: PHARMACOLOGY

ORG_NAME: RUTGERS BIOMEDICAL AND HEALTH SCIENCES

ORG_STATE: NJ

PI_NAMEs: ROTH, MONICA J. (contact)

PROGRAM_OFFICER_NAME: SAKALIAN, MICHAEL

PROJECT_TERMS: Address;Affinity;Area;Artificial Intelligence;Binding;Binding Proteins;Bioinformatics;Computer Assisted;design;Drug Design;drug discovery;env Gene Products;Foundations;Generations;Genes;Integrase;Knowledge;Lead;leukemia;Membrane Proteins;Modeling;Molecular;Mus;novel;novel strategies;Oncogenes;Orphan;Pathogenesis;programs;Protein Family;protein structure prediction;Proteins;receptor;Receptor Cell;Regulation;Research;small molecule;small molecule inhibitor;Specificity;Structure;Tissues;tool;Viral;virology;Virus;Virus-like particle

PROJECT_TITLE: Targeting retroviral and virus-like particles for gene and protein delivery


NIH_SPENDING_CATS: Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Health Services;Human Genome;Lung;Lung Cancer;Lymphatic Research;Pediatric;Pediatric Cancer;Prevention;Rare Diseases;Social Determinants of Health;Tobacco;Tobacco Smoke and Health

ORG_CITY: NEW YORK

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: NEW YORK UNIVERSITY SCHOOL OF MEDICINE

ORG_STATE: NY

PHR: PROJECT SUMMARY/ABSTRACT The Laura and Isaac Perlmutter Cancer Center (PCC) is a matrix cancer center that oversees and directs all cancer research and care in the NYU Langone Health (NYULH) system. Our 195 Members engage in basic, translational, clinical, and/or population research to address the needs of our large, diverse catchment area.

PI_NAMEs: KIMMELMAN, ALEC  (contact)

PROGRAM_OFFICER_NAME: BELIN, PRECILLA L

PROJECT_TERMS: Address;anti-cancer research;Area;Award;Basic Science;bench to bedside;Biology;Cancer Biology;Cancer Burden;cancer care;cancer cell;Cancer Center;Cancer Center Support Grant;Cancer Control;cancer education;cancer epidemiology;cancer genetics;cancer genome;cancer health disparity;Cancer Patient;cancer therapy;cancer type;Caring;Catchment Area;Cellular biology;Childhood Leukemia;Clinical;Clinical Cancer Center;Clinical Research;Clinical Trials;college;Communities;community engagement;Community Outreach;Comprehensive Cancer Center;Correlative Study;County;COVID-19;COVID-19 pandemic;Dana-Farber Cancer Institute;Disease;Disparity;Early Therapeutic-Clinical Trials Network;Education;Environmental Pollutants;Epidemiology;Epigenetic Process;frontier;Funding;Genome;Genomics;Goals;graduate student;Grant;Growth;Health;Health system;High School Student;Home;House Staffs;Immunology;Immunotherapy;improved;infection related cancer;Influentials;innovation;insight;Institution;inter-institutional;interest;Journals;junior high school;Laboratories;Laboratory Scientists;Lead;Leadership;Licensing;Long Island;Lymphoma;Malignant neoplasm of lung;Malignant neoplasm of urinary bladder;Malignant Neoplasms;medical schools;Medical Students;Medicine;Melanoma;member;Mentorship;Metabolism;New York;next generation;novel therapeutics;Nursing Students;Obesity;outcome disparities;Outcomes Research;Pathway interactions;Patient Care;patient oriented;Patients;Peer Review;Phase;Policies;Population;Population Research;Population Sciences;prevent;programs;Public Policy;public policy on tobacco;Publications;recruit;Research;Research Personnel;Resource Sharing;Schools;Science;Scientist;Signal Transduction;Strategic Planning;targeted therapy trials;Thinking;Time;tobacco control;Training;Training and Education;Translating;Translational Research;tumor immunology;undergraduate student;Underrepresented Minority;Universities

PROJECT_TITLE: Cancer Center Support Grant

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Cancer Centers Study Section (A)[NCI-A]


ORG_CITY: LOS ANGELES

ORG_NAME: CEDARS-SINAI MEDICAL CENTER

PHR: PROJECT NARRATIVE Cisplatin-based combination chemotherapy is the standard-of-care treatment for muscle invasive bladder cancer but 70% of patients do not respond. We discovered a novel mechanism by which puromycin-sensitive aminopeptidase, NPEPPS, is upregulated, and we have strong evidence supporting its interaction with volume- regulated anion channels (VRACs) to block import of cisplatin and other platins into cancer cells. The focus of this proposal is to characterize this novel mechanism and evaluate pharmacological inhibition of NPEPPS in combination with platin drugs in preclinical models with the objective of eventually improving patient outcomes.

PI_NAMEs: COSTELLO, JAMES CHRISTOPHER;THEODORESCU, DAN  (contact)

PROGRAM_OFFICER_NAME: VENKATACHALAM, SUNDARESAN

PROJECT_TERMS: Adjuvant Chemotherapy;Affect;Aminopeptidase;Animal Model;Anions;Antineoplastic Agents;Automobile Driving;Back;Binding;Biochemical;Biological Assay;Biophysics;cancer cell;Cancer cell line;Cancer Model;Cancer Patient;Candidate Disease Gene;Carboplatin;cell growth;Cell Proliferation;Cells;cellular imaging;Chemoresistance;chemotherapy;Chromatin;Cisplatin;Clinical;Combination Drug Therapy;Complex;Coupled;CRISPR screen;CRISPR/Cas technology;Cystectomy;Data;Dependence;design;Disease;Drug resistance;druggable target;Effectiveness;Foundations;Future;Genes;Growth;Human;Impairment;improved;improved outcome;In Vitro;in vivo;inhibitor;Kidney;knock-down;Malignant neoplasm of urinary bladder;Mass Spectrum Analysis;Mediating;Mediator;member;molecular modeling;muscle invasive bladder cancer;mutant;Mutate;Neoadjuvant Therapy;novel;novel strategies;Organoids;Outcome;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;pharmacologic;Phenotype;Physiological;Platinum;pre-clinical;Pre-Clinical Model;preclinical evaluation;Prognostic Factor;Prognostic Marker;Proteins;puromycin-sensitive aminopeptidase;reconstitution;Regulation;Residual Neoplasm;Resistance;response;Role;Site;Site-Directed Mutagenesis;standard of care;Testing;therapeutic evaluation;therapeutic target;translational therapeutics;Translations;tumor;tumor growth;Tumor Suppressor Proteins;whole genome

PROJECT_TITLE: NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 1 Study Section[MCT1]


ADMINISTERING_IC: DK

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

IC_NAME: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

NIH_SPENDING_CATS: Diabetes

ORG_CITY: PHILADELPHIA

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

ORG_STATE: PA

PHR: Project Narrative  Obesity and diabetes mellitus have reached epidemic proportions worldwide. The goal of this grant is to train the next generation of scientists at the medical student, pre-doctoral, and post-doctoral level to conduct research that will impact the prevention and treatment of diabetes and other endocrine disorders.

PI_NAMEs: SEALE, PATRICK ;STOFFERS, DORIS A (contact)

PROGRAM_OFFICER_NAME: CASTLE, ARTHUR

PROJECT_TERMS: Diabetes Mellitus;Endocrine;Metabolism

PROJECT_TITLE: Diabetes, Endocrine, and Metabolism

STUDY_SECTION: DDK

STUDY_SECTION_NAME: Diabetes, Endocrinology and Metabolic Diseases B Study Section[DDK-B]


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Digestive Diseases;Esophageal Cancer;Genetics;Human Genome;Infectious Diseases;Prevention;Rare Diseases;Stomach Cancer

ORG_DEPT: SURGERY

ORG_NAME: COLUMBIA UNIVERSITY HEALTH SCIENCES

PHR: PROJECT NARRATIVE To address fundamental questions regarding the cell-of-origin of distinct classes of gastric cancer, we will integrate novel mouse models, organotypic cultures of human and mouse cells using state- of-the-art single cell profiling and spatial transcriptional analyses. We will also explore the related issue of disease development by defining key transcriptional mediators of the progression to gastric cancer and then perform experimental validation. Taken together, our studies will address and resolve longstanding debates over the origins of gastric cancer while also defining possible targets to prevent cancer initiation.

PI_NAMEs: MANIATIS, SILAS ;NOWICKI-OSUCH, KAROL PIOTR;RYEOM, SANDRA  (contact)

PROGRAM_OFFICER_NAME: YASSIN, RIHAB R

PROJECT_TERMS: Address;angiogenesis;Angiogenic Factor;Atlases;Attenuated;Cadherins;Cancer Etiology;cancer initiation;candidate validation;CD44 gene;cell type;Cells;Cessation of life;Characteristics;Chromatin;Chromosomal Instability;Collaborations;Complex;Coupled;Data;Development;dietary;dietary nitrate;Diffuse;Diffuse gastric cancer;Disease;DNA Sequence Alteration;E-Cadherin;Endothelial Cells;Engineering;Environmental Exposure;Environmental Risk Factor;Epigenetic Process;epigenomics;Epithelial Cells;Epithelium;Esophageal Adenocarcinoma;Esophagogastric Junction;Esophagus;Evolution;Exposure to;functional genomics;Future;gastric cancer prevention;gastric corpus;gastric intestinal metaplasia;gastric tumorigenesis;gastroesophageal adenocarcinoma;Gastrointestinal tract structure;Gene Expression Profiling;Genetic;Genetic Transcription;Genetically Engineered Mouse;genome editing;Genome Stability;genomic aberrations;Genomics;Helicobacter;Helicobacter Infections;Helicobacter pylori;Histologic;Human;human tissue;Immune;In Vitro;in vivo;Individual;insight;Intervention;Intestines;Lesion;Link;Malignant - descriptor;Malignant neoplasm of esophagus;Malignant Neoplasms;malignant stomach neoplasm;Maps;Mediating;Mediator;member;Modeling;Molecular;molecular subtypes;mouse model;multiple omics;Mus;Mutation;Myeloid Cells;Myeloid-derived suppressor cells;Neoplasms;neoplastic;Nerve Growth Factors;Nitrates;Nomenclature;novel;Organoids;Pathway interactions;Phenotype;Play;Population;Premalignant Cell;prevent;Process;programs;Resources;Role;Sampling;Signal Transduction;single cell analysis;single cell technology;Stomach;stomach cardia;System;Technology;Testing;Time;Tissue Sample;Tissues;tool;TP53 gene;transcriptomic profiling;transcriptomics;Tumor Expansion;tumor initiation;tumor progression;Tumor Promotion;Tumor Suppressor Proteins;Uncertainty;Validation;Variant

PROJECT_TITLE: Initiation of Diffuse and Intestinal Non-Cardia Gastric Cancer


ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

NIH_SPENDING_CATS: Breast Cancer;Cancer;Women's Health Research

ORG_CITY: NOTRE DAME

ORG_DEPT: BIOLOGY

ORG_NAME: UNIVERSITY OF NOTRE DAME

ORG_STATE: IN

PHR: Project Narrative The metastasis of cancerous cells to distant and vital organs is responsible for approximately 90% of cancer mortalities, and it is clear that an important barrier to tumor progression and metastasis is the survival of cancer cells that are detached from the extracellular matrix (ECM). However, our understanding of the molecular mechanisms underlying the survival of ECM-detached cancer cells remains rudimentary. This proposal seeks to examine how a novel pathway involving RIPK1 and the degradation of mitochondria can restrict breast cancer progression.

PI_NAMEs: SCHAFER, ZACHARY T. (contact)

PROGRAM_OFFICER_NAME: SALNIKOW, KONSTANTIN

PROJECT_TERMS: 3-Dimensional;Address;Anchorage-Independent Growth;Anoikis;Antioxidants;Applications Grants;Biological;Biological Assay;Breast Cancer Cell;Breast Cancer Patient;breast cancer progression;cancer cell;Cancer Patient;cancer survival;Cancerous;Caspase;Cell Culture Techniques;Cell Death;Cell Survival;Cells;Cessation of life;combat;Complex;Data;Death Rate;design;Development;Disease;Disseminated Malignant Neoplasm;Distant;Epithelial Cells;Exposure to;Extracellular Matrix;FDA approved;in vivo;insight;Integrins;intravenous injection;Investigation;Knowledge;Link;Malignant Neoplasms;Mammary Neoplasms;Mammary Tumorigenesis;Mediating;Mitochondria;Molecular;Molecular Analysis;mortality;Necrosis;Neoplasm Metastasis;new therapeutic target;novel;novel strategies;novel therapeutic intervention;Nude Mice;Organ;Outcome;Pathway interactions;Patients;Phosphotransferases;Prognosis;programs;Protein Kinase Interaction;Proteins;Reactive Oxygen Species;Receptor Inhibition;Receptor Signaling;Receptor-Interacting Protein;Regulation;Role;Signal Transduction;Therapeutic;therapeutic development;Therapeutic Intervention;tumor;tumor progression;Tumor stage;tumorigenesis

PROJECT_TITLE: Mitophagy-Mediated Cell Death in Mammary Tumorigenesis

STUDY_SECTION: CAMP

STUDY_SECTION_NAME: Cancer Molecular Pathobiology Study Section[CAMP]


NIH_SPENDING_CATS: Biotechnology;Cancer;Ovarian Cancer;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Stem Cell Research - Nonembryonic - Non-Human;Women's Health Research

ORG_CITY: SAN DIEGO

ORG_NAME: SAN DIEGO STATE UNIVERSITY

PHR: Narrative Ovarian cancer is usually diagnosed at a late stage when survival is only about 10%, rendering this disease the deadliest gynecological malignancy. Disease recurrence is the major cause of mortality and despite a greater understanding of ovarian cancer biology there have been no significant improvements in mortality rates in the last five decades. Investigation of tumor cells that are resistant to chemotherapy and have the capacity to regenerate tumors is crucial for achieving cures for ovarian cancer patients.

PI_NAMEs: HOUSE, CARRIE DANIELLE (contact)

PROGRAM_OFFICER_NAME: BERA, TAPAN K

PROJECT_TERMS: Address;Adjuvant Chemotherapy;Aftercare;aldehyde dehydrogenases;Cancer Biology;cancer cell;cancer drug resistance;Cancer Patient;cancer recurrence;Cancer Relapse;cancer survival;Carboplatin;Cell Physiology;Cell Survival;cell type;Cells;Chemoresistance;chemotherapy;Chemotherapy-Oncologic Procedure;Clinical;Clinical Data;Clustered Regularly Interspaced Short Palindromic Repeats;Combined Modality Therapy;cytokine;Cytotoxic agent;Cytotoxic Chemotherapy;Data;Death Rate;design;Development;Diagnosis;Disease;Disease remission;Disease Resistance;Drug resistance;Early identification;Ensure;Environment;Event;Experimental Designs;Family;Family member;Genes;Goals;Human;Imaging technology;Immunocompetent;improved;inhibitor;interest;Investigation;Knock-out;Knowledge;Macrophage;Malignant Female Reproductive System Neoplasm;Malignant neoplasm of ovary;Malignant Neoplasms;Mediating;Morbidity - disease rate;mortality;mouse model;Natural regeneration;Neoadjuvant Therapy;neoplastic cell;NF-kappa B;NF-kappaB-inducing kinase;notch protein;novel;ovarian neoplasm;Paclitaxel;Pathway interactions;Patients;Play;Population;Proliferating;Property;Publishing;Recurrence;Recurrent disease;Recurrent tumor;Relapse;Reporter;Reproducibility;Research;Resected;Resistance;response;Role;Sampling;self-renewal;Signal Pathway;Signal Transduction;Solid Neoplasm;standard of care;stemness;Stimulus;Stromal Cells;targeted treatment;therapeutically effective;Tissues;transcription factor;transcriptome sequencing;tumor;tumor initiation;tumor microenvironment;tumor progression;United States;Work;Xenograft procedure

PROJECT_TITLE: Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse


ORG_CITY: SCOTTSDALE

ORG_NAME: MAYO CLINIC ARIZONA

ORG_STATE: AZ

PHR: NARRATIVE: OVERALL: Mapping the Cancer Complex System from Clinical MR Imaging of GBM The aim of our Mayo/Columbia CSBC Mathematical Oncology Systems Analysis Imaging Center (MOSAIC) is to build a conceptual framework to understand sex-specific glioma tissue state transitions and dynamics and the ways to interpret MRI relative to those changes MOSAIC leverages a large and growing core unique resource of radiographically-localized biopsies in glioma patients. In two projects, we will employ quantitative systems biology to quantify the dynamic glioma tissue state ecosystem and connections to routine clinical imaging. This will allow us to better understand glioma tissue states, their cellular cross-talk and how individual patients’ tissue state landscape will respond to therapy to ultimately drive new clinical trials that improve patient outcomes.

PI_NAMEs: CANOLL, PETER ;SWANSON, KRISTIN R (contact)

PROGRAM_OFFICER_NAME: DUECK, HANNAH RUTH

PROJECT_TERMS: Admixture;Affect;Age;Anatomy;Arizona;Atlas of Cancer Mortality in the United States;Bioinformatics;biological heterogeneity;Biology;Biopsy;Brain;Brain Neoplasms;brain parenchyma;Cell Nucleus;Cells;Classification;Clinic;Clinical;clinical imaging;Clinical Oncology;clinical translation;Clinical Trials;cohort;Collaborations;Communities;Complex;Computer Models;Dendritic Cell Vaccine;density;Detection;Diagnostic;Disease;Disease Progression;diversity and inclusion;driving force;Ecosystem;Evolution;Fostering;Future;Genetic;Glioblastoma;Glioma;Heterogeneity;Image;image archival system;Image Guided Biopsy;imaging facilities;imaging modality;Immunotherapy;improved;in vivo;in vivo imaging;Incidence;individual patient;Inflammation;insight;Inter-tumoral heterogeneity;lens;Machine Learning;Magnetic Resonance Imaging;Malignant neoplasm of brain;Malignant Neoplasms;Maps;mathematical model;Mathematics;Medical;men;Methods;Modeling;Molecular Analysis;Molecular Biology;Monitor;neoplastic;novel;Oncology;Operative Surgical Procedures;Organ;outreach;Patient Care;Patient-Focused Outcomes;Patients;Pattern;Persons;Phenotype;Physicians;Physics;Population;precision medicine;precision oncology;predictive modeling;radiological imaging;recruit;Research;Resources;response;Scientist;Series;sex;sex as a biological variable;Sex Bias;Signal Transduction;soft tissue;standard of care;System;Systems Analysis;Systems Biology;T-Lymphocyte;Therapeutic;Tissue Sample;Tissues;Training;transcriptome sequencing;treatment response;tumor;tumor growth;tumor microenvironment;tumor progression;Universities;Vaccine Therapy;Vision


NIH_SPENDING_CATS: Biomedical Imaging;Brain Cancer;Brain Disorders;Cancer;Neurosciences;Rare Diseases

PHR: NARRATIVE: ADMINISTRATIVE CORE The Administrative Core will be the primary touchpoint of the center, facilitating interactions between the two projects and three additional cores. The Administrative Core will also actively cultivate collaborations throughout the consortium with assistance from the Outreach Core, particularly through administering Intra-Center and Cross-Consortium Pilot Projects, hosting workshops and symposiums, and facilitating visiting faculty all while enhancing diverse perspectives on this critical topic. Co-PDs Swanson and Canoll will provide the central leadership in the Administrative Core, while the Center Program Administrator will provide day-to-day business, administrative and scientific management of Center activities.

PI_NAMEs: SWANSON, KRISTIN R (contact)

PROJECT_TERMS: Administrator;Advisory Committees;Aminolevulinic Acid;Area;Authorization documentation;Award;Biopsy;Businesses;career;clinical imaging;Collaborations;Communication;Communities;Core Biopsy;Data;data access;data exchange;data integration;data management;data sharing;Discipline;Educational workshop;Ensure;Evaluation;Faculty;Feedback;Fluorescence;Funding;Glioma;Grant;Growth;Image;Institution;Institutional Review Boards;interest;Leadership;Logistics;Machine Learning;Magnetic Resonance Imaging;Malignant Neoplasms;Mathematics;meetings;Monitor;neuro-oncology;Office of Administrative Management;Oncology;outreach;Pathology;Patients;Phenotype;Pilot Projects;Process;programs;Publications;Radiology Specialty;recruit;Regulation;Reproducibility;Research Project Grants;Resource Sharing;Resources;Suggestion;symposium;Systems Biology;Tissues;training opportunity;Visit;web site;Work

PROJECT_TITLE: MOSAIC: Administrative Core


NIH_SPENDING_CATS: Bioengineering;Cancer;Lung;Lung Cancer

ORG_CITY: CLEVELAND

ORG_DEPT: OTHER BASIC SCIENCES

ORG_NAME: CLEVELAND CLINIC LERNER COM-CWRU

ORG_STATE: OH

PHR: NARRATIVE Darwinian evolution drives the emergence of resistance to targeted therapy in cancer. We propose to use results from our in vitro evolutionary game assay to parameterize a computer model to allow us to predict 3-dimensional dynamics on clinically relevant timescales. Further, we will extend our assay to function in vivo, allowing the community to test mathematically derived evolutionary therapy hypotheses in preclinical models.

PI_NAMEs: MARUSYK, ANDRIY ;SCOTT, JACOB GARDINIER (contact)

PROGRAM_OFFICER_NAME: MILLER, DAVID J

PROJECT_TERMS: 3-Dimensional;abiraterone;actionable mutation;Address;anti-cancer research;Antibiotic Resistance;Automobile Driving;Biological;Biological Assay;Biological Process;Biology;Cancer Model;cancer therapy;Clinic;Clinical;Clinical Medicine;clinical translation;Clinical Trials;clinically relevant;Code;Communities;Complex;Computer Models;Data;design;Disease;Ecosystem;Epidermal Growth Factor Receptor;Evolution;Exhibits;experience;Extinction;Favorable Clinical Outcome;Fisheries;Game Theory;Generations;Genes;Glean;Grain;Growth;Heterogeneity;in silico;In Vitro;in vitro Model;in vivo;inhibitor;insight;interdisciplinary approach;Intuition;invention;Life;Literature;Malignant neoplasm of prostate;Malignant Neoplasms;mathematical model;Mathematics;Measurement;Measures;Methods;Modeling;multi-scale modeling;mutant;Mutation;neoplastic cell;New Agents;next generation;Non-Small-Cell Lung Carcinoma;novel;pathogen;Patients;Pesticides;Pharmaceutical Preparations;Phase II Clinical Trials;Phenotype;physical science;Population;Population Heterogeneity;Pre-Clinical Model;pressure;Process;Protein Tyrosine Kinase;Proteins;Qualitative Methods;Race;Refractory;Relapse;Research;Resistance;response;Role;spatiotemporal;success;System;targeted cancer therapy;targeted treatment;Testing;Theoretical model;Theoretical Studies;theories;Therapeutic;Therapeutic Intervention;therapy design;Time;tool;Translating;trial design;tumor;two-dimensional;Tyrosine Kinase Inhibitor;Work

PROJECT_TITLE: Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modeling


ORG_CITY: LA JOLLA

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

PI_NAMEs: BROIDE, DAVID H (contact)

PROGRAM_OFFICER_NAME: DONG, GANG


PROJECT_TITLE: GSDMA and Airway Remodeling.


ED_INST_TYPE: COMPUTER CENTER

NIH_SPENDING_CATS: Bioengineering;Clinical Research;Data Science;Networking and Information Technology R&D (NITRD)

ORG_CITY: PITTSBURGH

ORG_NAME: CARNEGIE-MELLON UNIVERSITY

PHR: Public Health Relevance Statement: The Infrastructure Component (IC) of the HuBMAP Integration, Visualization & Engagement  (HIVE) Collaboratory will provide the open data platform for study of multi-scale tissue  organization and function through 3D biomolecular tissue maps in the spatial framework of the  human body. The studies enabled on this platform will facilitate comparisons across individuals,  organs, tissues, and cells to characterize normal function and variation, leading to deeper  understanding of underlying mechanisms of variation or disease, and ultimately pointing to  interventions for disease prevention or treatment.

PI_NAMEs: BLOOD, PHILIP D. (contact);SILVERSTEIN, JONATHAN C.

PROGRAM_OFFICER_NAME: CONROY, RICHARD

PROJECT_TERMS: 3-Dimensional;Anatomy;Architecture;Area;Atlases;Automation;Biological Assay;Cells;Cloud Computing;Collaborations;collaboratory;Communities;community engagement;community partners;computerized data processing;Data;data ingestion;data pipeline;data platform;Data Set;data standards;data visualization;Development;Disease;disorder prevention;Documentation;Ensure;flexibility;Friction;Histologic;Human;Human BioMolecular Atlas Program;Human body;Human Resources;human tissue;Hybrids;Individual;Infrastructure;Ingestion;International;interoperability;Intervention;Joints;knowledge graph;Leadership;Maps;Measurement;member;Modeling;Molecular;multimodality;Ontology;open data;Organ;Phase;Production;Provider;public health relevance;Research;Resolution;Resources;Services;Supercomputing;tissue mapping;Tissues;tool;Translating;Universities;Variant;Vision;Visualization

PROJECT_TITLE: Flexible Hybrid Cloud Infrastructure for Seamless Integration and Use of Human Biomolecular Data and Reference Maps [1 of 5]


ADMINISTERING_IC: HD

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Cancer;Data Science;Networking and Information Technology R&D (NITRD);Pediatric;Pediatric Cancer;Rare Diseases

ORG_NAME: CHILDREN'S HOSP OF PHILADELPHIA

PHR: PROJECT NARRATIVE Under this supplement the Kids First Data Resource will provide the requisite continued support of the scalable cloud-based resources required for the continued operations and use of the Portal, associated services, CAVATICA, and additional AWS-hosted platforms as well as the transition of AWS storage resources to the Cancer Research Data Commons (CRDC). Support will also continue for data harmonization and integration across pediatric cancer and structural birth defect datasets, providing a unified discoverable framework for cross- disease research.

PI_NAMEs: CARROLL, ROBERT J;DIGIOVANNA, JACK ;FERRETTI, VINCENT ;GROSSMAN, ROBERT L.;HEATH, ALLISON ;RESNICK, ADAM CAIN (contact);TAYLOR, DEANNE MARIE;VOLCHENBOUM, SAMUEL

PROGRAM_OFFICER_NAME: FOURNIER, MARCIA VASCONCELLOS

PROJECT_TERMS: anti-cancer research;Child;Clinical Data;cloud based;Cloud Service;cloud storage;cohort;computing resources;Consultations;Data;Data Commons;Data Coordinating Center;data exchange;data exploration;Data Files;data framework;data harmonization;data ingestion;data integration;data interoperability;data portal;data resource;Data Set;Data Storage and Retrieval;database of Genotypes and Phenotypes;Development;Disease;empowerment;Ensure;Environment;Fast Healthcare Interoperability Resources;genomic data;Malignant Childhood Neoplasm;Malignant Neoplasms;Metadata;National Institute of Child Health and Human Development;operation;parent grant;parent project;Participant;programs;Research;Resources;Sampling;Services;Source;Structural Congenital Anomalies;sustainable resource;Technology;United States National Institutes of Health;Variant

PROJECT_TITLE: KF Supplement -- Sustainable and Optimized Cloud Resources on behalf of the Kids First DRC

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1(70)-R]


NIH_SPENDING_CATS: Data Science;Networking and Information Technology R&D (NITRD)

ORG_DEPT: BIOSTATISTICS & OTHER MATH SCI

PHR: Public Health Relevance Statement: Uniform processing of many disparate data types reduces friction in integrating disparate data between  modalities, tissues, and data providers, allowing clinicians and public health experts to find biological  and clinically-relevant insights in large biomolecular, spatial, and imaging datasets. We will expand on  our previous work to link the results of large-scale HuBMAP data processing to the Human Reference  Atlas (HRA) efforts, ensuring that HuBMAP datasets are highly represented in the HRA.

PI_NAMEs: PATEN, BENEDICT ;RUFFALO, MATTHEW  (contact);TEICHMANN, SARAH AMALIA

PROJECT_TERMS: Anatomy;Atlases;Biological;Cells;cellular imaging;clinically relevant;Collaborations;Computational algorithm;computational pipelines;computerized data processing;computerized tools;Data;Data Display;data modalities;Data Set;Development;differential expression;dimension reduction;Disparate;Ensure;Foundations;Friction;Human;Human BioMolecular Atlas Program;Image;imaging Segmentation;indexing;innovation;insight;Joints;Link;Maps;Methods;Modality;Phase;Process;Production;Provider;Public Health;public health relevance;Salmon;single-cell RNA sequencing;Standardization;tissue mapping;Tissues;Work

PROJECT_TITLE: Computational tools for uniform processing and integration of human reference atlas data [2 of 5]


ADMINISTERING_IC: AR

ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

IC_NAME: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Eye Disease and Disorders of Vision;Lung;Physical Injury - Accidents and Adverse Effects;Wound Healing and Care

PHR: Narrative There is increasing concern that civilian populations might be exposed to chemical toxicants. The primary objective of the Rutgers CounterACT Center of Excellence is to develop medical countermeasures against chemicals threats. A team of researchers has been assembled capable of rapid advancement of candidate drugs through the regulatory process so that they can be used to enhance the medical response capabilities of the United States.

PI_NAMEs: LASKIN, JEFFREY D (contact)

PROGRAM_OFFICER_NAME: KOCH, PETER

PROJECT_TERMS: Advanced Development;Animal Model;Anti-Inflammatory Agents;Antibodies;Area;Basic Science;Centers of Research Excellence;chemical release;chemical threat;Chemical Weapons;Chemicals;Clinical;Clinical Trials;Collaborations;Cornea;Corneal Injury;Development;Dexamethasone;Disease;drug candidate;drug development;drug discovery;Drug Kinetics;drug repurposing;education research;Effectiveness;efficacy evaluation;Emergency Situation;Event;exposed human population;Exposure to;Eye Injuries;FDA approved;Formulation;Funding;Generations;Goals;Grant;Human;improved;Inhalation;Injury;innovation;Lead;lead candidate;lead optimization;Lung;lung injury;Mechlorethamine;Medical;medical countermeasure;meetings;Military Personnel;Miniature Swine;model development;Modeling;Morbidity - disease rate;mortality;Mustard;Mustard Gas;novel;novel therapeutics;Ointments;Organ;Oxytetracycline;Pathogenesis;Pathology;Pharmaceutical Chemistry;Pharmaceutical Preparations;pharmacologic;Pharmacologic Substance;Pharmacology;Poisoning;Population;Postdoctoral Fellow;pre-Investigational New Drug meeting;Process;Productivity;programs;Rattus;Research;research and development;Research Personnel;response;Rodent;skills;Skin;Skin injury;Students;System;Testing;Therapeutic Intervention;Therapeutic Uses;Tissues;TNF gene;Toxic effect;toxicant;Toxicology;Training;translational model;United States;United States National Institutes of Health;Universities;vapor;Vesicants;Work;Workforce Development;World War I

PROJECT_TITLE: Rutgers University CounterACT Center of Excellence


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Dissemination and Implementation Research;Drug Abuse (NIDA only);Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Opioid Misuse and Addiction;Opioids;Physical Injury - Accidents and Adverse Effects;Social Determinants of Health;Substance Misuse

ORG_CITY: PROVIDENCE

ORG_NAME: RHODE ISLAND HOSPITAL

ORG_STATE: RI

PHR: PROJECT NARRATIVE  Medications for opioid use disorder (MOUD) are an effective treatment in the community and among incarcerated individuals, yet they are offered in very few correctional settings nationwide. The criminal justice (CJ) system offers a unique opportunity to engage individuals in treatment initiation, given the high prevalence of opioid use disorder (OUD) in jails and prisons and the high risk of opioid overdose upon release. The study will compare treatment outcomes between extended-release buprenorphine (XR-B) to treatment-as-usual sublingual buprenorphine (SL-B) in a CJ setting and conduct a mixed-methods process evaluation which will characterize the facilitators of and barriers to the implementation of this novel treatment modality.

PI_NAMEs: BERK, JUSTIN  (contact)

PROGRAM_OFFICER_NAME: SU, SHELLEY

PROJECT_TERMS: addiction;Address;Adherence;Buprenorphine;career;Caring;Cessation of life;Clinical;Clinical Medicine;Clinical Trials;cohort;Communities;community setting;Correctional Institutions;cost;court;COVID-19 pandemic;Criminal Justice;Data;Data Set;Databases;Dedications;Development;Disparity;Dropout;Drug Screening;effective therapy;Effectiveness;effectiveness clinical trial;Enrollment;Epidemic;Ethics;Evaluation;Event;evidence base;experience;Familiarity;follow-up;Foundations;Funding;Future;General Population;Goals;Grant;health care settings;health management;High Prevalence;high risk;illicit opioid;implementation barriers;implementation evaluation;implementation facilitators;implementation framework;implementation outcomes;implementation science;Imprisonment;Individual;Injectable;Institution;interest;Intervention;Interview;Jail;Life;Link;Literature;marginalized population;Measures;medication for opioid use disorder;Mentors;Methodology;Methods;Modality;Monitor;mortality;novel;opioid mortality;opioid overdose;opioid use;opioid use disorder;Overdose;Parents;patient oriented;Patients;Persons;Pharmaceutical Preparations;Pilot Projects;Policies;Population;prevent;primary outcome;Prisons;process evaluation;programs;Public Health;Publishing;racial disparity;Randomized, Controlled Trials;Reach, Effectiveness, Adoption, Implementation, and Maintenance;reincarceration;Research;Research Personnel;Resources;Rhode Island;Risk;Sampling;Scientist;secondary outcome;Site;skills;social stigma;Standardization;Statutes and Laws;Surveys;System;Time;Training;treatment as usual;treatment center;treatment comparison;Treatment outcome;trial comparing;United States National Institutes of Health;uptake;Urine;Vulnerable Populations;Work

PROJECT_TITLE: Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: A Pilot Randomized Controlled Trial


ORG_CITY: IRVINE

ORG_NAME: UNIVERSITY OF CALIFORNIA-IRVINE

ORG_STATE: CA

PHR: Program Narrative The Ethiopian ICEMR proposes to host the 2024 annual workshop for the 11 International Centers of Excellent for Malaria Research and scientific advisory group meetings for the Ethiopia and Uganda ICEMRs. The workshop will facilitate data sharing and collaboration among malaria researchers, and enhance the development of new malaria diagnosis and control tools and strategies.

PI_NAMEs: YAN, GUIYUN  (contact)

PROGRAM_OFFICER_NAME: RAO, MALLA R

PROJECT_TERMS: Administrative Supplement;Area;Collaborations;data sharing;Development;Educational workshop;Ethiopia;Ethiopian;experience;Feedback;Funding;Group Meetings;Individual;interest;international center;Logistics;Malaria;Malaria Diagnosis;member;National Institute of Allergy and Infectious Disease;Participant;programs;Protocols documentation;Public Health;Recommendation;Research;Research Personnel;Resources;tool;Travel;Uganda;United States National Institutes of Health

PROJECT_TITLE: 2024 ICEMR Annual Workshop and Scientific Advisory Group Meeting


ADMINISTERING_IC: AG

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease Related Dementias (ADRD);Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Behavioral and Social Science;Biomedical Imaging;Brain Disorders;Cardiovascular;Cerebrovascular;Dementia;Neurodegenerative;Neurosciences;Nutrition;Physical Activity;Prevention;Vascular Contributions to Cognitive Impairment and Dementia (VCID)

ORG_CITY: PISCATAWAY

ORG_DEPT: MISCELLANEOUS

ORG_NAME: RUTGERS, THE STATE UNIV OF N.J.

PHR: PROJECT NARRATIVE This integrated training and research proposal focuses on the longitudinal associations of two physical activity- related measures of energy expenditure with cognition and Alzheimer’s disease (AD) biomarkers among older adults who are cognitively normal, as well as those with mild cognitive impairment and mild AD dementia. Potential biological and genetic factors that may modify and/or mediate these associations will also be examined.

PI_NAMEs: DOUGHERTY, RYAN JAMES (contact)

PROGRAM_OFFICER_NAME: MARTIN, DAMALI

PROJECT_TERMS: Acceleration;Aging;Alzheimer's Disease;Alzheimer's disease related dementia;Alzheimer’s disease biomarker;Amyloid;apolipoprotein E-4;Baltimore;Biological;Biological Markers;Brain;brain volume;cardiorespiratory fitness;career;career development;cerebral atrophy;Cerebrovascular Circulation;Clinical Research;Cognition;Cognitive;Cognitive aging;cognitive change;cognitive function;cognitive performance;cohort;cost;Data;Dementia;Development;Development Plans;Diagnostic;Dimensions;Disease;Disease Progression;educational atmosphere;Energy Metabolism;Exercise;Genetic;Genotype;Goals;hippocampal atrophy;Impaired cognition;Individual;insight;Intervention;Knowledge;Life Style;lifestyle factors;Link;Literature;Longitudinal Studies;Magnetic Resonance Imaging;Measures;Mediating;Mentored Patient-Oriented Research Career Development Award;Mentored Research Scientist Development Award;Mentorship;mild cognitive impairment;Mitochondria;Muscle Mitochondria;Musculoskeletal System;neuroimaging;novel;older adult;Older Population;Outcome;Oxygen;Pharmaceutical Preparations;Physical activity;Physiological;Positron-Emission Tomography;Predictive Value;programs;prospective;Publishing;Research;Research Personnel;Research Proposals;research study;Research Training;responsible research conduct;Rest;Risk;Risk Assessment;Risk Reduction;Role;sex;Skeletal Muscle;skills;specific biomarkers;Specificity;Statistical Data Interpretation;tau aggregation;tau Proteins;Techniques;Therapeutic;Time;Training;Translational Research;Walking;walking speed;Work

PROJECT_TITLE: Energy expenditure, cognitive function, and biomarker features of Alzheimer's disease

STUDY_SECTION: AGCD

STUDY_SECTION_NAME: Career Development For Early Career Investigators Study Section [AGCD-2]


NIH_SPENDING_CATS: Bioengineering;Genetics

ORG_CITY: DAVIS

ORG_NAME: UNIVERSITY OF CALIFORNIA AT DAVIS

PHR: PROJECT NARRATIVE Bacteria can be engineered as live therapeutics for broad biomedical applications. The proposed research will enable the creation of safe and effective therapeutic bacteria.

PI_NAMEs: TAN, CHEEMENG  (contact)

PROGRAM_OFFICER_NAME: SALVADOR MORALES, CAROLINA

PROJECT_TERMS: Address;Bacteria;Cells;Chemicals;Clustered Regularly Interspaced Short Palindromic Repeats;commensal bacteria;Communities;Devices;Disease;Dose;Drug Delivery Systems;drug synthesis;Ecosystem;Engineering;Ensure;Future;Gene Expression;Genes;Growth;Human body;Hybrids;information processing;interest;Measures;Metabolism;microdevice;Molecular;mutant;Mutation;Patients;preservation;prevent;Proliferating;Protein Biosynthesis;Proteins;Research;Safety;Site;Stimulus;Synthetic Genes;Therapeutic;therapeutically effective;tool;Work

PROJECT_TITLE: Dissecting the non-growing-but-active state of a hybrid bacteria-material microdevice

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CB-U(55)R]


ADMINISTERING_IC: FD

IC_NAME: FOOD AND DRUG ADMINISTRATION

ORG_CITY: DURHAM

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: DUKE UNIVERSITY

PHR: PROJECT NARRATIVE The U.S. Food and Drug Administration (FDA), through its Office of Medical Policy, has sought to advance regulatory science, policy, and procedures to address a range of critical public health topics, including drug development, drug approval, bioresearch monitoring, human subject protection, and post market surveillance methods and systems. The Robert J. Margolis, MD, Institute for Health Policy at Duke University (Duke- Margolis) proposes to support the FDA in advancing its medical policy development through rigorous collaborative research and convening activities from design, planning, and execution, through to synthesis, drafting, and communication of findings. This builds on Duke-Margolis and FDA's 15-year track record of partnership and leverages Duke-Margolis's skill as a neutral third-party convener to develop and deliver trusted, high-impact stakeholder engagement and research materials on priority regulatory and public health issues.

PI_NAMEs: HAMILTON LOPEZ, MARIANNE  (contact)

PROGRAM_OFFICER_NAME: LAUDA, MARK

PROJECT_TITLE: Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, and Policy Development of Medical Products for Ongoing Public Health Activities, U01 Clinical Trial Not Allowed

STUDY_SECTION_NAME: Special Emphasis Panel[ZFD1 CDER-T (12)]


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Physical Injury - Accidents and Adverse Effects;Wound Healing and Care

ORG_DEPT: DERMATOLOGY

ORG_NAME: UNIVERSITY OF ALABAMA AT BIRMINGHAM

PHR: Narrative Building on our previous validation studies conducted in highly relevant animal models, the successful completion of the proposed studies will provide at least one novel, highly effective and safe mechanism-based formulation of small molecules for attenuating painful cutaneous blistering/inflammation caused by exposure to chemical warfare arsenical vesicants and, perhaps, other similar agents. These studies are crucial for moving the newly developed formulation to clinic. The outcome of the proposed research is likely to have a significant impact on human health protection in the event of accidental or intentional mass population exposure to vesicant chemicals used in warfare.

PI_NAMEs: ATHAR, MOHAMMAD  (contact)

PROJECT_TERMS: absorption;Accidents;Acids;Acute;Animal Model;Anti-Inflammatory Agents;Antidotes;Antioxidants;Arsenic;Arsenicals;Asia;Attenuated;Award;Biological;Biological Assay;British;Bulla;Cell Death;Characteristics;chelation;chemical threat;Chemical Warfare;Chemical Weapons;Chemicals;China;ChIP-seq;Clinic;Clinical;clinical candidate;clinical translation;Complex;Cutaneous;Cysteine;Dangerousness;Data;Dermatology;design;Development;Dose;Drug Formulations;effective therapy;efficacy evaluation;EIF-2alpha;Emulsions;endoplasmic reticulum stress;Event;experience;Exposure to;Family suidae;FDA approved;Formulation;Funding;Generations;Germany;Health protection;Human;Human Rights;Inflammation;Inflammatory Response;inhibitor;Injury;Intervention;Investigation;Italy;Japan;Laboratories;lead optimization;Lesion;lewisite;Maximum Tolerated Dose;Mediating;Miniature Swine;Modeling;Molecular;Molecular Chaperones;Molecular Target;mouse model;Mus;Mustard Gas;Needles;novel;Outcome;Oxides;Pain;Pathogenesis;Pathway interactions;Pharmaceutical Preparations;Phosphorylation;Poison;Population;porcine model;pre-clinical;programs;propellant;Protective Agents;protein folding;protein misfolding;Proteins;Publishing;Reactive Oxygen Species;Records;Reporting;Research;response;Risk;Role;Safety;Scientist;Security;Seminal;Signal Transduction;skin damage;Skin injury;skin lesion;small molecule;Syria;System;Therapeutic;Therapeutic Agents;therapeutic lead compound;Tissues;Topical application;Toxic effect;Toxicology;transcription factor;transcriptome sequencing;Translations;treatment strategy;United States National Institutes of Health;USSR;Validation;validation studies;Vesicants;weapons;web site;World War I;World War II

PROJECT_TITLE: Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Bioengineering;Eye Disease and Disorders of Vision;Neurosciences

ORG_NAME: DREXEL UNIVERSITY

PHR: PROJECT NARRATIVE Those who are blind or visually impaired suffer from an inability to transform visual information into behaviorally relevant representations to guide selection of appropriate actions. This project seeks to derive the algorithms for sensorimotor transformations that can guide technologies to restore visual-motor behaviors through neuroprosthetics. This project also seeks to uncover the underlying mechanisms for these algorithms that provide targets for restoring sensorimotor transformations in neurodegenerative diseases or neurodevelopmental disorders.

PI_NAMEs: VON REYN, CATHERINE R (contact)

PROGRAM_OFFICER_NAME: OSBORNE, LESLIE CAROL

PROJECT_TERMS: Afferent Neurons;Algorithms;Anatomy;Animals;Behavior;Behavioral;behavioral response;Biological;biophysical model;Biophysical Process;Biophysics;blind;cell type;Cells;Code;combinatorial;Computer Models;Data;Development;Drosophila melanogaster;Electrophysiology (science);Environment;Genetic;Grant;Individual;insight;Invertebrates;Ion Channel;knock-down;Knowledge;Link;Location;Maps;Methods;Modeling;Molecular;Motor;motor behavior;Motor output;neural;neural circuit;Neurodegenerative Disorders;Neurodevelopmental Disorder;Neurons;neuroprosthesis;Neurosciences;Optic Lobe;optogenetics;Outcome;Output;Pathway interactions;Pattern;Play;Population;presynaptic;Process;programs;Property;Research;Resolution;response;RNA Interference;Role;Sensory;sensory processing disorder;Shapes;Stimulus;Synapses;System;Technology;Testing;Validation;Visual;Visual impairment;visual information;visual motor;visual stimulus

PROJECT_TITLE: Neural algorithms underlying diversity in visual feature integration

STUDY_SECTION: SPC

STUDY_SECTION_NAME: Mechanisms of Sensory, Perceptual, and Cognitive Processes Study Section[SPC]


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Clinical Research;Depression;Mental Health;Mental Illness;Neurosciences

ORG_CITY: BERKELEY

ORG_DEPT: PSYCHOLOGY

ORG_NAME: UNIVERSITY OF CALIFORNIA BERKELEY

PHR: PROJECT NARRATIVE Our findings have the potential to describe the neural computations that form the basis for amotivation, a known transdiagnostic factor across several psychiatric and neurological disorders, including depression and schizophrenia. This research can therefore enable endophenotypic assessment of risk for these disorders and severity of motivational impairments in subclinical populations, providing a potential biomarker to aid in diagnosis and treatment outcome research, and facilitating development of and tests of efficacy for therapies aimed at reducing these impairments. This work carries promising future directions for studying motivational impairments in depression, schizophrenia, Alzheimer’s, and Parkinson’s, and to improve well-being and increase productivity in the general population.

PI_NAMEs: SHENHAV, AMITAI  (contact)

PROGRAM_OFFICER_NAME: ROSSI, ANDREW F

PROJECT_TERMS: Adult;Alzheimer's Disease;Anterior;Attention;Behavior;career;Chronic;cingulate cortex;Cognitive;cognitive control;Computer Models;Cost Analysis;Costs and Benefits;Cues;daily functioning;Decision Making;Development;Diagnosis;Diagnostic;Diagnostic Factor;Disease;disorder risk;Dissociation;Dorsal;efficacy testing;Electroencephalography;endophenotype;Environment;Evaluation;Event-Related Potentials;expectation;experience;Feedback;Functional Magnetic Resonance Imaging;functional magnetic resonance imaging/electroencephalography;Future;General Population;Goals;health goals;Impairment;improved;Incentives;indexing;Individual;Individual Differences;information processing;insight;Investments;Learning;Major Depressive Disorder;Measures;Mental Depression;Mental disorders;Modeling;Motivation;Multivariate Analysis;Nervous System Disorder;neural;neural circuit;novel;Outcomes Research;Output;Parkinson Disease;Participant;Pattern;Personal Satisfaction;Persons;Population;potential biomarker;Productivity;Prognosis;programs;Psyche structure;Research;response;Rewards;Risk Assessment;Schizophrenia;Severities;Signal Transduction;Source;Stimulus;Techniques;Testing;Treatment Efficacy;Treatment outcome;Update;Work

PROJECT_TITLE: Neural and computational mechanisms of motivation and cognitive control

STUDY_SECTION: CP

STUDY_SECTION_NAME: Cognition and Perception Study Section[CP]


NIH_SPENDING_CATS: Neurosciences

ORG_CITY: SAINT LOUIS

ORG_DEPT: ANATOMY/CELL BIOLOGY

ORG_NAME: WASHINGTON UNIVERSITY

PHR: Project Narrative: Metabolic flexibility is essential for cellular and organismal survival in times of energetic stress. Our work aims to decipher the molecular pathways that enable energetic cells like neurons to fine-tune their metabolic programs to energy demand and thereby perform highly complex functions.

PI_NAMEs: ASHRAFI, GHAZALEH  (contact)

PROGRAM_OFFICER_NAME: ANSONG, CHARLES KWAKU

PROJECT_TERMS: Bioenergetics;Biosensor;Cell Energetics;Cell Physiology;cell type;Cells;cellular imaging;Communities;Complex;Coupled;Diabetes Mellitus;Disease;Endocytosis;Energy Metabolism;Eukaryotic Cell;flexibility;Gene Expression Profile;Genomics;Glycolysis;Goals;Laboratories;Leigh Disease;Metabolic;Metabolic dysfunction;metabolic imaging;Metabolism;Mitochondria;Molecular;Muscle Fibers;Myopathy;Neurons;new technology;novel;optical imaging;Oxidative Phosphorylation;Pathway interactions;Process;Production;programs;Regulation;Research;Stress;Synaptic Vesicles;tool;transcriptomics;Work

PROJECT_TITLE: Cellular mechanisms of bioenergetic plasticity

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CB-M(55)R]


NIH_SPENDING_CATS: Clinical Research;Cystic Fibrosis;Data Science;Lung;Microbiome;Orphan Drug;Rare Diseases

ORG_CITY: HANOVER

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: DARTMOUTH COLLEGE

ORG_STATE: NH

PHR: Cystic fibrosis is a devastating genetic disease that involves multiple organ systems and leads to premature death; therapeutic advances have extended lifespans and improved quality of life, but patients still suffer from airway infections, in addition to CF-related diabetes, digestive complications, and inflammatory responses. Our Center catalyzes new research in preclinical drug development, gut disease and diabetes and changes in patient microbiomes. We believe that these phenomena are interconnected, and that parallel investigations, coupled by powerful new data-science strategies can find new therapeutic approaches for CF patients by understanding the complex underlying biology.

PI_NAMEs: MADDEN, DEAN R (contact)

PROGRAM_OFFICER_NAME: EGGERMAN, THOMAS L

PROJECT_TERMS: Acceleration;Address;Affect;Antibiotics;antimicrobial;Archives;Area;Award;base;Basic Science;Bioinformatics;Biology;Biostatistics Core;Body System;career development;Cessation of life;Chronic;Clinical;Clinical Research;Coculture Techniques;cohort;Collaborations;commensal microbes;Communities;community center;Complex;complex data;Coupled;Cystic Fibrosis;cystic fibrosis patients;cystic fibrosis related diabetes;Cystic Fibrosis Transmembrane Conductance Regulator;Data;Data Science;Data Set;data submission;Databases;Development;Diabetes Mellitus;Disease;dysbiosis;Ecology;Educational workshop;Endowment;Epithelium;Evaluation;extend lifespan;Extramural Activities;Faculty;forging;Fostering;Foundations;Functional disorder;Funding;gastrointestinal;Genetic Diseases;Goals;gut dysbiosis;gut microbes;host-microbe interactions;Immune;Immune response;Immunity;improved;improved outcome;Inflammatory Response;innovation;insight;Institution;interest;interoperability;Intervention;Investigation;Liver diseases;Lung;Malnutrition;Mediating;member;Metabolic;Microbe;microbial;microbial community;microbiome;Mining;Mission;Modeling;Monitor;Mutation;National Institute of Diabetes and Digestive and Kidney Diseases;novel;novel strategies;novel therapeutic intervention;novel therapeutics;open data;Organ;Outcome;Pancreatitis;Pathogenesis;pathogenic microbe;Patients;Pharmaceutical Preparations;Pilot Projects;pre-clinical;Preclinical Drug Development;premature;programs;Quality of life;recruit;Research;Research Personnel;Resources;Respiratory Tract Infections;Services;Signal Transduction;Structure;Symptoms;synergism;System;systemic inflammatory response;Therapeutic;Tissues;tool;Training;Translational Research;translational study;Virulence;Work

PROJECT_TITLE: DartCF: The Dartmouth Cystic Fibrosis Research Center